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     Introduction 
 
 
Once patients with cirrhosis experience decompensation, mortality risk increases. 
The causes of mortality in decompensated cirrhosis patients are many fold. Both 
hepatic dysfunction and non hepatic causes have been implicated in causation of 
death in decompensated cirrhotic patients 
Not all patients admitted with decompensated cirrhosis deteriorate. Many improve 
with intensive treatment and are discharged. However some patients deteriorate in 
spite of intensive treatment and die. 
The short-term prognosis of acutely ill patients with cirrhosis is influenced by the 
degree of hepatic insufficiency and by dysfunction of extrahepatic organ systems 
Child-Pugh score has been the reference for many years for assessing the prognosis 
of cirrhosis. However, Child-Pugh score has important limitations, making it 
difficult to categorize patients according to their own disease severity. The model 
for end-stage liver disease (MELD) score, which was originally designed for 
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assessing the prognosis of cirrhotic patients undergoing transjugular intrahepatic 
portosystemic shunt (TIPS), is a continuous score relying on three objective 
variables. 
However both CTP score and MELD are associated with many limitations.  Mainly 
they are not used used in assessing prognosis  during hospitalization. Many other 
biochemical and hematological variables can be associated with mortality and can 
be predictive. 
Assessment of prognosis during hospitalization mortality can have important role 
in triaging for level of care 
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                                                Aim of the study 
 
1. To find out the causes of hospital mortality in patients admitted with  
decompensated cirrhosis of liver 
2. To evaluate for the biochemical and hematological parameters that are  
related to  mortality during hospitalization 
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                                                  Review of literature 
 
 Cirrhosis – Natural history 
 
Any  patient  with cirrhosis carries a risk of specific life-threatening complications 
such as variceal bleeding, sepsis, or hepatorenal syndrome. There is in addition a 
significant risk of nonspecific life-threatening complications due to the association 
of frequent comorbidities. The  course of the disease is characterized by a long 
standing phase of compensated cirrhosis, followed by the occurrence of specific 
complications. It has been shown that after 10 years of diagnosis, the probability of 
developing decompensated cirrhosis is around 60%, ascites being the most 
common complication (׽50%).[1] Once patients have developed the first evidence 
of decompensation, complications tend to accumulate and life expectancy is 
reduced markedly.  
The course of cirrhosis varies  extremely  from patient to patient due to several 
factors, including hepatic synthetic function (or “hepatic reserve”), the cause of 
cirrhosis, the possibility of stopping or slowing the underlying damaging process to 
the liver, and the occurrence of liver malignancy. Therefore, establishing a 
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prognosis in a given patient with cirrhosis remains a challenging issue. In addition 
to the estimation of life expectancy, more complex issues must be taken into 
account, such as the capacity of a cirrhotic patient to withstand a given therapeutic 
intervention. Over the last decade, complex issues emerged with the availability of 
liver transplantation, namely, the optimal timing for transplantation and, on a 
collectivity basis, the optimization of allocation policy in a context of organ 
shortage. 
Even though the course of cirrhosis varies according to several factors, the need for 
prognostic models and scoring systems is obvious in order to manage individuals 
faced with different therapeutic options 
 
Child’s Score 
Child’s score, originally termed Child-Turcotte score, was proposed more than 30 
years ago.[3] It was initially  designed for predicting the outcome after surgery for 
portal hypertension (portocaval shunting and trans-section of the esophagus) in 
patients with cirrhosis. Child-Turcotte score had included two continuous variables 
(bilirubin and albumin) and three discrete variables (ascites, encephalopathy, and 
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nutritional status) which were selected empirically because they were felt to have 
their own influence on the prognosis.[4] 
A modified version was proposed ׽20 years ago termed Child-Pugh score .[5] The 
change in this modified version was that nutritional status was replaced by 
prothrombin time. Initially, prothrombin time was expressed in seconds. However, 
a limitation is the fact that prothrombin can also be expressed as either a 
percentage of normal (prothrombin index) or as international normalized ratio 
(INR), this latter being now the reference in many countries. The original cut-off 
values was 4 and 6 seconds for prothrombin time prolongation correspond 
approximately to a prothrombin index of 50% and 40%, respectively. These same 
values correspond roughly to an INR of 1.7 and 2, respectively. Child-Pugh score 
corresponds to the total  points for each item. According to the sum of these points, 
patients can be categorized into different Child-Pugh grades A (5 to 6 points), B (7 
to 9 points), or C (10 to 15 points). The variables that are included in Child-Pugh 
score are not specific markers of the synthesis (albumin and prothrombin) and 
elimination (bilirubin) functions of the liver. Changes in serum albumin may be 
also related to increased vascular permeability,[6] especially in cases of sepsis, and 
large-volume ascites.[7] Similarly, increased bilirubin  can be  a consequence of 
impaired renal function, hemolysis, or sepsis.[8] Prolonged prothrombin time can be 
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a consequence of an intravascular activation of coagulation factors during sepsis.[9] 
Overall, the individual components of the Child-Pugh score encompass a very 
broad spectrum of conditions than the single impairment of “liver function.” Child-
Pugh score as a whole can also be considered a marker of the multiorgan changes 
resulting from cirrhosis. 
 
Child Score 
Measure one Two three 
Bilirubin (mg/dl) <2 2-3 >3 
Albumin (g/dl) >3.5 2.8 – 3.5 <2.8 
INR <1.7 1.71 – 2.20 >2.20 
Ascites None Mild Severe 
Encephalopathy None  Grade I-II (or suppressed with 
medication) 
Grade III-IV (or 
refractory) 
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Assessment of prognosis by Child Pugh score 
Points  Class  One year survival  Two year survival 
5 – 6 A 100% 85% 
7 – 9 B 81% 57% 
>10 C 45% 35% 
 
Applications 
Studies shown that Child-Pugh score is an independent prognostic marker in the 
settings of ascites,[10] ruptured esophageal varices,[11] alcoholic cirrhosis,[12] 
hepatitis C virus- (HCV-) related cirrhosis,[13] primary biliary cirrhosis (PBC),[14] 
primary sclerosing cholangitis (PSC),[15] and Budd-Chiari syndrome.[16] Child-
Pugh score, can be easily calculated at the bedside and has been widely used for 
selecting candidates for resection of hepato cellular carcinoma[17] and nonhepatic 
surgery.[18]  
Limitations 
The five variables of Child-Pugh score were selected empirically. It can be 
anticipated that not all are independent predictors of prognosis. For example, 
albumin and prothrombin time may be somewhat redundant. Including both 
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variables in a single score may result in overweighting their own influence on this 
score. 
The cut-off value for each variable has also been empirically selected. There is no 
evidence that moving from one class to the next one translates into a proportional 
increased change in mortality risk. For example, patients with serum bilirubin 
above 6 mg% may be under-scored with Child-Pugh, because the limit for the 
upper class of bilirubin is only 3 mg%. In addition, the limits for qualitative 
variables like ascites and encephalopathy are still vague and can be influenced by 
subjective interpretation. 
The five variables of Child-Pugh score are also empirically given the same weight, 
which is also questionable. Multivariate analysis has also shown that the proper 
weight of predictive factors is quite variable. Taking an example, the weight of 
INR is three times as high as that of bilirubin in MELD score.[24]  
Child-Pugh score also does not take into account specific variables, serum 
creatinine in particular, which had been shown to have a determinant impact on the 
prognosis of cirrhosis.[10,24] Similarly, it has been shown that the addition of other 
markers like markers of portal hypertension, such as esophageal varices, portal 
  
13 
 
blood velocity, and hepatic venous pressure gradient (HVPG), would improve the 
accuracy of Child-Pugh score.[20,25,26]  
Finally, Child-Pugh score does not take into account the etiology of cirrhosis and 
the possibility of stopping  the damaging process to the liver. This limitation is 
especially relevant in patients with ethanol related cirrhosis or with hepatitis B 
virus- (HBV-) related cirrhosis with viral replication. 
 
 
Meld Score 
 
Definitions 
 Child score was originally designed for assessing the prognosis of cirrhotic 
patients undergoing surgical treatment of portal hypertension.  MELD score was 
designed for assessing the prognosis of cirrhotic patients undergoing transjugular 
portosystemic intrahepatic shunt (TIPS).[24] Multivariate analysis using Cox 
regression analysis showed that among a list of various pre-determined variables, 
four variables had an independent impact on survival, namely bilirubin, creatinine, 
INR, and the cause of cirrhosis (alcoholic and cholestatic versus other causes). To 
lessen the influence of extreme values, the natural logarithm of bilirubin, INR and 
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creatinine were entered into the model. Based on logistic regression analysis, a 
coefficient was attached to each variable, according to the weight of each variable 
on mortality risk. In the original series, the resulting score was  more accurate than 
Child-Pugh score for predicting survival after TIPS. 
With the availability of liver transplantation, attention moved from the 
management of portal hypertension to waiting list mortality and organ allocation 
policy in patients listed for transplantation. Therefore, a slightly modified risk 
score, termed the MELD score, was tested in populations of cirrhotic patients for 
assessing early (3 months) mortality risk after placement on the waiting list.[28] 
This modified score was proved to be a robust marker of early mortality which 
could be generalized to patients with various etiologies of cirrhosis and various 
degrees of severity. As excluding the variable “cause of cirrhosis” had a minimal 
impact on the model accuracy, a simplified version of MELD score including  
three objective variables (bilirubin, creatinine, and INR) was eventually proposed 
for easier use [29] According to this modified score, patients with bilirubin and 
creatinine values below 1 mg/dL are rounded off to 1 mg/dL to avoid negative 
logarithmic values. Likewise patients with INR below 1 are rounded off to 1. 
Whatever the individual values, the score is empirically capped at a value of 40. 
Therefore, MELD score represents a continuous variable ranging from 6 to 40.  
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Applications 
MELD score has been adopted from 2002 for organ allocation to patients listed for 
liver transplantation [30]. According to the MELD-based policy, patients with the 
highest score of MELD have a priority for organ allocation. MELD score has also 
been adopted in several European countries as well as in South America.  
In addition to organ allocation, several studies have also confirmed that MELD 
score is a reliable tool for predicting outcome after TIPS.[31,32] The “c” statistic of 
an event represents a global estimate of the ability of a score to predict an event. 
This statistic is derived from the area under the receiver operating characteristic 
curve and ranges from 0 to 1. A “c” statistic of 0.5 means that the score is not of 
value for predicting a given event. A “c” statistic of 1 means that the score is 
perfect and best predicts a given event (a goal which is rarely achieved in clinical 
practice). The “c” statistic of the MELD score for predicting 1-year survival after 
TIPS is around 0.7, which means that it is clinically useful. MELD score has also 
proved to be a reliable marker of 1-year and 5-year survival across a broad 
spectrum of liver diseases including alcoholic cirrhosis and alcoholic hepatitis.[33] 
In addition, MELD score has also been shown to be a good prognostic marker in 
cases of variceal bleeding,[34] spontaneous bacterial peritonitis,[35] and hepatorenal 
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syndrome.[36] Independent of the cause of cirrhosis, high MELD score was shown 
to be associated with a decrease in residual liver function as measured by 
functional liver function tests.[37] 
Limitations 
All the variables entered in the MELD model have been empirically selected, 
because they were felt to have an influence on the outcome or, more simply, 
because they were available.  
The three variables entered in the MELD score (bilirubin, creatinine, and INR) are  
objective variables (in contrast to ascites and encephalopathy, the grading of which 
is subjective). For example there are substantial inter laboratory variations in INR 
depending on the methods used for determination. Among all the three variables of 
MELD score, INR has the highest multiplicative value. Therefore the variations in 
INR may translate in up to 20% differences in MELD score.[38] In  individuals with 
cirrhosis, substantial changes in serum creatinine may occur, especially in those 
undergoing large-volume paracentesis and/or receiving diuretics. There is a poor 
agreement among different creatinine assays, especially with serum bilirubin 
rising.[39] Overall, MELD score was not as objective as it was expected to be. 
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A major limitation of MELD is the need for computation, which makes it less 
friendly to use than Child-Pugh score at the bedside. The logarithmic 
transformation has been chosen to optimize the statistical model. Originally, this  
model and the derived score were not designed to be routinely used in clinical 
practice. With the expansion of use of MELD score in many fields of hepatology, 
the need for computation represents a source of difficulties. In addition, there are 
also no clear-cut values of MELD score for easily categorizing individual patients 
according to their own mortality risk. 
 
Meld Score Derivatives 
 
MELD-Na 
With the implementation of the MELD score, refractory ascites was removed from 
the list of variables used for assessing the prognosis of cirrhosis. Ascites was 
shown to be associated with  poor prognosis.[40] It was felt that in patients with 
refractory ascites, normal creatinine, and preserved hepatic function, MELD could 
be under-scored. It was shown that persistent ascites and low serum sodium 
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identified a subset of patients with relatively low MELD score (below 21) and a 
high risk of early death.[41]  
Serum sodium is a very simple, readily available, and objective marker of disease 
severity. During cirrhosis, hyponatremia results from various causes including  
solute-free water retention. Systemic arterial vasodilation leads to the release of 
antidiuretic hormone which, in turn, induces dilutional  hyponatremia. The 
activation of these mechanisms in turn correlates with the degree of portal 
hypertension.[42] Hyponatremia can be considered to be indirect marker of portal 
hypertension during cirrhosis. 
Various studies have shown that hyponatremia is a strong predictor of early 
mortality, independent of MELD score.[41,43-45] Changes in survival are especially 
pronounced for sodium concentrations  from 120 to 135 mEq/L. Within this 
sodium range, a decrease in serum sodium of 1 mEq/L corresponds to a 12% 
decrease in 3-month probability of survival.[45] A modified score including serum 
sodium, termed MELD-Na, has been proposed as an alternative to MELD score 
for assessing prognosis.[44] The accuracy of MELD-Na was shown to be only 
slightly superior to that of MELD in candidates for transplantation.[43-45] The effect 
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of hyponatremia was found to be higher in patients with low MELD score 
compared with those with high MELD score.  
A limitation for the incorporation of serum sodium into MELD is that during 
cirrhosis, marked changes in serum sodium concentration can result from several 
factors, including the administration of diuretics and intravenous hypotonic fluids. 
For example, the administration of diuretics leads to a 4 mEq/L decrease in serum 
sodium, on average.[46] In some patients the decrease may reach up to 10 mEq/L. In 
contrast to diuretics, the use of V2-receptor antagonists for treating refractory 
ascites is encouraging. These agents would induce a significant increase in serum 
sodium. Therefore, serum sodium is not as objective as it was thought to be. 
Further validation and practical guidelines is needed regarding the incorporation of 
sodium to avoid misclassification. 
MELD-XI 
INR is the variable in MELD which has the highest weight in MELD score. 
Unfortunately, INR is not interpretable in patients receiving anticoagulation 
therapy. Patients with cirrhosis may receive anticoagulation due to portal vein 
thrombosis, an underlying prothrombotic state, or any other concomitant 
condition.[47] Most patients with Budd-Chiari syndrome may also receive 
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anticoagulation with anti-vitamin K agents. In this population also INR is 
artificially increased. Using MELD score in these contexts would result in 
overestimating the disease severity.  
With the important  aim of overcoming this difficulty, a modified MELD score 
termed MELD-XI (for MELD excluding INR) has been proposed.[48] This modified 
score significantly relies only on bilirubin and creatinine. Therefore, neither INR 
nor any other marker of coagulation is taken into account for calculating the score. 
The coefficients ascribed to creatinine and bilirubin during calculation of  MELD 
have been changed to obtain the optimal linear correlation between MELD and 
MELD-XI. Therefore, the adjusted coefficients mean that patients with a given 
MELD-XI score have a mortality risk comparable to that of patients with 
interpretable INR and a similar MELD score. 
The validation of MELD-XI score signifies that its accuracy for assessing 3-month 
mortality risk is comparable to that of MELD (with a c statistic of ׽0.83).[48] 
Omission of INR and the use of adjusted coefficients did not change much the 
predictive accuracy of the score, which is somewhat surprising since INR is a 
strong, independent prognostic marker in the original series from which MELD 
score is derived. Noted that both creation and validation of MELD-XI score have 
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been made in populations of patients who did not receive anticoagulation. Patients 
who are receiving anticoagulation are expected to have co-morbidities and/or a 
different natural history. These patients may have specific risk profiles with a 
higher risk compared with patients without thrombotic complications. Therefore, 
further validation and studies in this particular population are needed. 
 
 
Delta MELD 
 
It can be anticipated that taking into account changes in MELD score over time 
may add prognostic information.[49] Patients who have a rapid increase in MELD 
over time might be expected to have a worse outcome than those with stable or 
even decreasing MELD score. Delta MELD is defined as the difference between 
current MELD and the lowest MELD measured within 30 days prior to current 
MELD. The Delta MELD was shown to be predictive of early mortality in patients 
with cirrhosis. However, delta MELD was not predictive of mortality when entered 
into a multivariate model with current MELD score.[50] These results suggest that 
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current MELD score is the only predictor of mortality regardless of how that score 
was reached.  
Prognosis Related to Specific Causes of Cirrhosis 
Alcoholic Cirrhosis and Alcoholic Hepatitis 
A particularity of alcoholic cirrhosis is that the majority of patients with high 
disease severity indexes do have superimposed alcoholic hepatitis. Alcoholic 
hepatitis is a potentially reversible condition, which means that some of these 
patients are likely to improve within the first months following discontinuation of 
alcohol. Such patients may return to a state of compensated cirrhosis. Evidence has 
shown that corticosteroids improve short-term survival in patients with severe 
alcoholic hepatitis.[51] Therefore, it would be difficult to assess the prognosis of 
patients with alcoholic cirrhosis without taking into account the existence of 
alcoholic hepatitis and, in those with severe alcoholic hepatitis, response to 
steroids. 
In most surveys, severe alcoholic hepatitis has been defined by a “discriminant 
function” above 32 .[52] In addition to this discriminant function, generally termed 
as “Maddrey score” (or Maddrey discriminant function), several specific scores 
have been created to predict early mortality in patients with severe alcoholic 
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hepatitis.[53,54] The more general MELD score has also been assessed in this setting. 
MELD score proved to be as efficacious as or even superior to the original 
Maddrey discriminant function.[55,56] However, none of these scores takes into 
account the progression over time and the response to steroids which, again, may 
be determinant.  
HBV- and HCV-Related Cirrhosis 
Recently, major advances have been achieved in the treatment of chronic HBV 
infection with the advent of antinucleot(s)ide analogues. Patients with 
decompensated HBV-related cirrhosis receiving antiviral therapy have a biphasic 
survival pattern. Mortality rate within the first 6 months after initiation of antiviral 
therapy is ׽15%.[58] After the first 6 months, mortality rate is 10 times lower. In 
the subgroup of patients who survive more than 6 months, 3-year survival exceeds 
85%. Compared with historical controls, patients with HBV-related 
decompensated cirrhosis receiving antinucleot(s)ide analogues have better survival 
rates. Based on a large cohort of patients with decompensated HBV-related 
cirrhosis receiving lamivudine, a specific prognostic score has been proposed . 
This score incorporates three variables: bilirubin, creatinine, and the presence of 
HBVDNA before treatment. It is somewhat paradoxical that patients with 
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undetectable HBV-DNA before initiation of antiviral therapy had a better survival. 
Indeed, it could have been expected that only those with evidence of viral 
replication (those who are positive for serum HBVDNA) would benefit from 
antiviral therapy. Other data suggest that 20% of patients initially considered for 
transplantation can eventually be removed from the waiting list after receiving 
adefovir-dipivoxil as a result of clinical improvement.[59]  
Advances in the treatment of HCV infection have been more limited, although 
significant. In patients with HVC-related cirrhosis, sustained virological response 
to interferon was shown to improve long-term outcome by reducing the incidence 
of liver-related complications.[60] However, the combination of interferon and 
ribavirin is generally contraindicated in patients with decompen-sated cirrhosis. 
There is no specific model for predicting the outcome according to viral load, 
genotype, and response to therapy. 
PBC 
PBC is one of the causes of cirrhosis for which specific prognostic scores were 
first proposed.[61,62] The aim of scoring was to determine the optimal timing for 
transplantation. The Mayo risk score for PBC includes four objective variables and 
one subjective variable (i.e., edema). It has been shown that the probability of 
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survival without transplantation for a risk score of 7.8 is 63% and 39% at 1 and 2 
years, respectively. It has also been shown that the risk of post-transplant mortality 
increases significantly when the risk score exceeds 7.8. Therefore, it is 
recommended that patients be referred to transplantation centers before reaching 
this value.  
PSC 
The course of PSC is much more variable than PBC. It has been shown that the 
specific risk score (termed Mayo risk score for PSC) is more accurate than Child-
Pugh for predicting survival, especially in patients with less-advanced disease.[64] 
This score allows the identification of three groups at low (score < 0), intermediate 
(0 ≤ score > 2), or high (score ≥ 2) risk. Five-year survival is above 90% in patients 
at low risk while it is less than 40% in patients at high risk.  
 
 
Prognosis in the Setting of the Intensive Medical Care Unit 
In general, the prognosis of cirrhotic patients admitted to the intensive care unit 
(ICU) due to multiorgan failure is very poor. Mortality rates in patients with failure 
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of two or three organ systems are estimated to be around 75% and 95%, 
respectively.[69] Mortality is much higher than that of noncirrhotic patients with 
multiorgan failure. For example, mortality rate among noncirrhotic patients with 
failure of two or three organ systems in a context of severe sepsis is around 26% 
and 34%, respectively.[70] The poor outcome of cirrhotic patients with multiorgan 
failure results from a rapid alteration of liver function, a limited capacity for liver 
regeneration, and the absence of efficient artificial liver support systems. 
Predicting the outcome in this context may help optimize resource utilization and 
triage. However, it must be kept in mind that  not all patients admitted to the ICU 
have a fatal outcome. In particular, some patients may be efficiently managed with 
aggressive management. 
In the particular setting of IMCU, it was reasonably assumed that Child-Pugh and 
MELD score have significant limitations for predicting very short-term survival. 
The more general Acute Physiology and Chronic Health Evaluation (APACHE) 
II[71] and sequential organ failure assessment (SOFA) scores[72] have been 
extensively validated in ICU admitted patients. SOFA score is a relatively complex 
score based on respiration, coagulation, liver function, cardiovascular status, 
neurological status, and renal function parameters. In cirrhotic patients admitted to 
the ICU, the accuracy of SOFA score was shown to be superior to that of 
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APACHE II and Child-Pugh score with a c statistic of 0.94.[69] Although the 
assessment of MELD score has been limited in this context, it seems that its 
prognostic value is lower than that of general ICU scores.[73]  
Overall, general ICU scores seem to be superior to “liver-oriented” prognostic 
scores in this context. In particular, whether multiorgan failure is the consequence 
of terminal illness alone or the consequence of one or more iatrogenic factors may 
weight heavily on the probability of recovery 
Prognosis in the Particular Setting of Non transplant Surgery 
Independent of liver resection for HCC, the possibility is relatively high that 
patients with cirrhosis will require some form of surgery (whether intra- or extra-
abdominal) at some time. But, patients with cirrhosis also represent a population at  
high risk of surgical morbidity and mortality. Recent reports indicate that in this 
population, in-hospital mortality may be as high as 10 to 20%, even though it can 
be assumed that most patients were carefully selected.[65,66] Mortality is the result 
of a high rate of postoperative decompensation of cirrhosis (especially in cases of 
intra-abdominal surgery) and an increased risk of bacterial infections. 
The issue of surgery and cirrhosis depends on presence of an alternative to surgery. 
When nonsurgical alternatives exist, prognostic markers should help justify the risk 
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of surgery. Child-Pugh score has been used in the last decade for addressing these 
issues. Recently, MELD score has also been assessed for predicting non-transplant 
surgical mortality.[65] In general, there is an approximately  1% increase in 
mortality risk per MELD point below a score of 20 and  a 2% increase in mortality 
risk per MELD point over 20.[65] Mortality is also higher for intra-abdominal 
surgery (up to 25%) compared with other types of surgery.  
The issue of “rescue” transplantation in cirrhotic patients who had severe 
decompensation and profound liver insufficiency after liver resection is also 
important. Indeed, cirrhotic patients have limited liver regeneration capacity. It has 
been shown that the persistence of a decrease in prothrombin index below 50% of 
normal (INR of ׽1.7) and an increase in serum bilirubin above 50 μmol/L on 
postoperative day 5 is associated with a 60% risk of early mortality.[68] These 
criteria allow early identification of patients who may need emergency 
transplantation, provided there is no general contraindication 
Prognosis in the  Setting of Transplantation 
It has been clearly shown that waiting time is not an accurate marker of waiting list 
mortality,[27] the “sickest first” policy has been widely adopted for organ allocation, 
with the aim of reducing waiting list mortality. Until now, liver transplantation has 
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been the main application for MELD score. MELD score is a robust marker of 
early mortality in cirrhotic patients across a wide spectrum of causes. It is a 
continuous score based on three readily available and relatively objective variables. 
Patients with particular conditions such as HCC can receive extra points 
corresponding to a given mortality risk. MELD can be updated in each patient 
according to the progression of the disease. 
The implementation of MELD in the United States has been associated with a 
reduction in waiting list mortality.[30] In parallel, this “sickest first” policy has been 
associated with an increasing number of patients with advanced cirrhosis 
undergoing transplantation. Importantly, this shift in the indications for 
transplantation did not affect post-transplantation survival. In other words, 
transplanting patients with high MELD score does not necessarily translate into a 
significant increased post-transplant mortality, except for extreme values (over 30 
to 35).[74,75] As HCC patients receive extra points, the implementation of MELD 
score also led to a significant decrease in the waiting list dropouts related to 
excessive tumor growth, without affecting post-transplant survival.[76]  
 MELD score proved highly efficient for prioritizing patients who are at high risk 
of dying without transplantation. However, an original approach consisting of 
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comparing liver transplant recipients’ survival to that of comparable candidates 
without transplantation offered the possibility of assessing the transplant survival 
benefit. This comparison showed that transplant survival benefit steadily increased 
with increasing MELD score.[77] A very important finding is that only patients with 
a MELD score exceeding 15 to 17 derive a significant benefit from transplantation. 
Patients with a lower MELD would have a higher risk of dying from 
transplantation than they have of dying from the complications of cirrhosis. 
Transplantation would be futile in this subgroup. 
However, a subset of patients with low MELD score and uncommon complications 
such as hepatopulmonary syndrome or mild portopulmonary hypertension are at 
high risk of dying in the absence of transplantation. 
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              Materials and Methods 
 
Cirrhotic patients admitted to the Section of Gastroenterology of Govt Stanley 
Medical College and hospital, a tertiary hospital, from January 2010 to may 2011 
were studied. 
Patients with decompensated cirrhosis liver who died during admission were 
selected as cases. Patients admitted with cirrhosis and its complications and who 
improved with treatment followed by discharge were selected as controls. Cases 
and controls were selected in a blinded manner. 
Data  collected  included  demographics; etiology  of  cirrhosis;  indication  for  
hospital admission;  presence  or  absence  of  decompensation  and portal 
hypertension;  and  the  corresponding  Child Pugh, MELD, and MELD-Na scores. 
Other hematological and biochemical markers were studied. Ethical committee 
approval was obtained for the study 
The diagnosis of cirrhosis was made by clinical evaluation and with help of 
investigations.  The clinical  diagnosis  of  cirrhosis  was  made  by  a history  of  
portal  hypertension  excluding  other etiology, impaired liver function tests, 
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impaired clotting   parameters,   ultrasonographic   or computer  tomographic  
criteria. 
The  Child-Pugh,  MELD  and  MELD Na scores  were  computed  for  each  
patient  on admission.  The MELD  score and MELD Na score  was  calculated 
according  to  the  original  formula  proposed  by the Mayo clinic group 
The  principal  study  outcome  was  hospital mortality.  
 The  cause  of  death  was  also determined.  
Exclusion criteria-  
Patients with portal hypertension not due to primary cirrhosis of liver were 
excluded. Patients with cirrhosis complicated by hepatocellular carcinoma were 
also not selected for this study 
Statistical Analysis:   Hematological, biochemical, scoring systems and clinical  
variables were reported as mean + SD, and group comparisons between cases and 
controls  were  carried  out using the independent sample t test. Univariate analysis 
and multiple forward stepwise logistic regressions were  used  to  identify  clinical  
and biochemical parameters directly correlated with mortality 
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                                                                   Results 
 
Total number of cases are 70. 
Total number of controls are 70. 
Both cases and controls were compared and found to be age and sex matched. 
Both cases and control groups contained predominantly male patients, 91.4% and 
94.3% respectively. 
The Mean age of cases is 46.33 years  and the mean age of controls is 45.56 years. 
The mean duration of disease in cases was 20.01 months while the mean duration 
of disease in controls is 12.76 months. 
The most common cause of liver dysfunction was found to be ethanol related. 
The number of hepatic and non hepatic complications in both groups was similar 
and most patients had 2 or more comorbid conditions. 
The most common cause of admission was hepatic encephalopathy in both groups. 
The other reasons for admission are renal insufficiency, refractory ascites, upper 
gastrointestinal bleeding 
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While evaluating for Chlid status in both groups, 11.4 % of patients in both groups 
had Child’s A cirrhosis.  48.6% of cases had Child’ s B cirrhosis while 52.9% of 
controls had Child’s B cirrhosis. 40.0% cases and  35.7% controls had Child’s C 
cirrhosis 
The mean MELD and MELD-Na was significantly higher for the cases group 
compared to the control group i.e 24.47  & 18.4 for MELD and 29.10  & 23.54 for 
MELD-Na for the cases and controls respectively 
The most common causes of death are due to cirrhosis related complications 
associated with decompensation like hepatic encephalopathy, hepato renal 
syndrome and upper gastrointestinal bleeding. A small number of patients died due 
to non cirrhosis related complications most commonly infections. 
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                                                                            Demographics 
 Cases Controls 
Total number 70 70 
Gender Males -64:Females-6 Males-66; Females-4 
Age (Years) 46.33 45.56 
 complications related to hepatic 
decompensation (Mean)  
2.20 1.90 
Extra hepatic complications (Mean) 0.17 0.3 
Etiology (Number) 
Alcohol 44 45 
Viral 15 14 
Others 11 11 
CTP (Number) 
A 8 8 
B 34 38 
C 28 25 
MELD (Mean) 24.47 18.4 
MELD –Na (Mean) 29.10   23.54 
TC (Mean) 11662.86 8170.24 
% neutrophilia (Mean) 75.01 69.99 
Platelet count (Mean) 1,10.200 1,23,871.43 
Sodium (Mean) 123.986 128.146 
Albumin (Mean) 2.313 2.346 
SGPT (Mean) 45.834 43.581 
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Univariate  analysis  was  performed  on  all variables .  
A p value less than 0.05 was considered statistically significant. 
This analysis revealed that increasing levels of MELD, MELD- Na, serum 
creatinine,   INR,  WBC , neutrophilia and duration of disease   were 
significantly  associated  with  increased  risk  of death. 
 Cases (Mean) Controls (Mean) P Value 
Duration of disease  20.01 12.76 0.001 
Child status 7.8 8.9 0.86 
MELD 24.47 18.40 0.001 
MELD Na 29.19 23.54 0.001 
Platelet 110200.00 123871.43 0.336 
TC 11662.86 8170.34 0.004 
% of neutrophils 75.01 69.99 0.007 
Hemoglobin 8.963 8.645 0.358 
APTT 34.36 32.13 0.114 
INR 1.859 1.55 0.008 
Creatinine 1.993 1.1093 0.001 
SGPT 69.36 47.69 0.039 
Albumin 2.313 2.346 0.5 
Sodium 123.986 128.146 0.076 
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On  multivariate  forward  stepwise logistic  regression,  an  elevated  WBC  
count (p=0.02, OR 1.2)and creatinine (p=0.003, OR 1.2)   were the only factors 
significantly associated with death 
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                                   Discussion 
 
 
 
The ability to objectively estimate patient risk for in hospital mortality  outcomes  
is  a  challenging undertaking . 
The  Child-Pugh  system  is  an  important component  of  the  prognostic  
evaluation  of cirrhotic  patients,  although,  this  traditional scoring  has  several  
shortcomings.  This  issue intensified  the  search  for  a  continuous  disease 
severity  score  system  that  used  more  objective, readily  verifiable  parameters,  
which  could  be validated as a measure of liver disease severity, or predictor of 
mortality. 
Child-Pugh score has been the reference for assessing the prognosis of cirrhosis for 
about three decades. The longevity of the Child-Pugh score can be explained by its 
empirical simplicity, its intuitiveness, and, overall, its good accuracy across a 
broad spectrum of causes and specific situations. Recently,  MELD score emerged 
as a “modern” alternative to Child-Pugh score. There is no clear evidence that 
MELD is superior to Child-Pugh score in terms of accuracy. Studies comparing 
these scores have shown that the accuracy of Child-Pugh score for predicting 3-
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month to 3-year survival is not always inferior to that of MELD score.[4] In 
addition, for many physicians, Child-Pugh score remains more convenient to use at 
the bedside and more explicit than MELD score. 
MELD scoring system found individually to be superior over Child-Pugh in some 
reports. 
In my study, the aim was to evaluate the in hospital mortality association of the 2 
scoring systems – CHILD and MELD along with MELD sodium and also various 
clinical, hematological and biochemical parameters 
 
 MELD score has several strengths compared with Child-Pugh. The variables 
incorporated into the MELD score are simple and more objective. The weight of 
each variable has been determined by statistical analysis. MELD is a continuous 
score, which makes it more convenient for scoring individuals within large 
populations. In addition to organ allocation, MELD score has been validated across 
a large spectrum of causes of liver diseases. All these reasons make the MELD 
score likely to be the core tool for assessing the prognosis of cirrhosis in the future. 
By using MELD score, it can be reasonably assumed that physicians will get 
landmarks as simple as those they had with Child-Pugh score. 
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The  Child- Pugh score uses two very subjective variables in its  calculation  -  
portosystemic  encephalopathy and  ascites. 
MELD  uses objective variables in  their  computation. MELD  uses  prothrombin  
time  INR,  serum bilirubin,  and  serum  creatinine  levels. In addition to these 
variables, MELD sodium uses sodium levels for computation 
Bacterial infections are a frequent and severe complication  of  cirrhosis. Cirrhotic  
patients have an acquired immune deficiency because of dyshomeostasis  and  
malnutrition.  All host defense systems are compromised. 
In my study, the result of the multivariate logistic analysis showed that an elevated  
WBC  count  was  associated  with  in-hospital mortality. 
On univariare analysis in my study, mean duration of disease was the clinical 
demographic which was found to significantly correlate with in hospital mortality. 
In my study, Child score was not found to correlate with in hospital mortality, but 
both MELD and MELD Na were found to correlate significantly with in hospital 
mortality. 
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Though hyponatremia was found in previous studies to correlate with early 3 
month mortality, it was not significantly correlated with in hospital mortality in 
my study. 
My analysis also revealed that increasing levels of serum creatinine,   INR,  WBC  
and neutrophilia were significantly  associated  with  increased  risk  of death 
The present study is limited by the omission of the arterial blood gas examination 
as a result of logistics. Presence of ABG would have facilitated calculating 
APACHE score. 
A previous studies by Wehler et al(69)  to assess and compare the prognostic  
accuracy  of  the  Child-Pugh  classification, the  Acute  Physiology  and  Chronic  
Health  Evaluation (APACHE) II system and the Sequential Organ Failure 
Assessment (SOFA) for predicting hospital mortality showed that  the  
discriminatory power of the SOFA to predict short-term mortality in critically ill 
patients with cirrhosis is  superior to the APACHE II and Child-Pugh systems. 
Also Prognostic scoring systems cannot replace the clinical evaluation of the 
patient.  
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The present study also confirms that Child score is not predictive of short term 
mortality. Features of multiple organ involvement like raised renal parameters, 
coagulopathy and leukocytosis are associated with early or in hospital mortality 
In a similar study conducted by Ira I Yu et al comparing in hospital prognosis  
among  cirrhotic  patients: Child-Pugh  versus  APACHE  III versus  MELD  
scoring  systems concluded that  the APACHE III scoring system is superior to 
Child-Pugh and MELD scoring systems for prognosticating in-hospital mortality 
among decompensated cirrhotic patients.  In the present study, as ABG could not 
be performed for all patients, APACHE could not be assessed. However 
components of the APACHE score like creatinine and leukocytosis showed 
relation to in hospital mortality.  
The limitations of this present study is the lack of follow up of the control group 
once the patients have been discharged.  
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Comparison to previous study by Wehler et al  
 Wehler study Present study 
Studied population 143 patients 140 patients ( 70 case  & 70 
controls) 
Study methodology Prospectively followed for up 
to 180 days or until mortality 
whichever was earlier 
Prospectively followed only 
during the time of admission and 
separated into cases or controls 
based on mortality or discharge 
Aim of the study Compare the predictive 
accuracy of CTP, APACHE-II 
and SOFA for predicting 
hospital mortality 
Study the causes of mortality and 
Look for association with 
mortality of various 
hematological parameters, 
biochemical values and scores 
like CTP, MELD and MELD 
sodium 
Results of the study CTP, APACHE and SOFA all 
predicted in hospital mortality 
but SOFA had the highest 
association 
Mortality is associated with 
increasing Duration of disease, 
leukocytosis, neutrophilia, 
creatinine, INR, SGPT, MELD 
and MELD Sodium values 
Similarity of the studies Multiple system involvement 
is associated with mortality 
Early mortality related to factors 
associated with a systemic 
inflammatory response syndrome 
Disparity between the 
studies 
CTP correlated with in hospital 
mortality 
CTP was not significantly 
different in the mortality group 
compared to the control group 
Advantage of my study No control group Presence of control  
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                         Comparision to a previous study by Ira I Yu et al  
 Ira I Yu et al Present study 
Objective of study To evaluate the prognostic accuracy of 
CP vs. APACHE III vs. MELD for 
predicting in-hospital  mortality  
among  decompensated  cirrhotic  
patients 
Study the causes of mortality and 
Look for association with mortality 
of various hematological 
parameters, biochemical values and 
scores like CTP, MELD and 
MELD sodium 
Methods 64 patients studied (29 mortality &35 
non mortality Pts) & CTP, . APACHE 
III and MELD calculated 
140 patients studied (70 cases and 
70 controls) and hematological 
parameters, biochemical values and 
scores like CTP, MELD and 
MELD sodium  related to mortality 
studied 
Results of the study The APACHE III scoring system is 
superior to Child-Pugh and MELD 
scoring systems for prognosticating in-
hospital mortality among 
decompensated cirrhotic patients 
Components of APACHE III like 
INR & creatinine, MELD & 
MELD Na are related to in-hospital 
mortality. CTP not associated with 
in-hospital mortality 
Advantage of my 
study 
Smaller studied group (64) Larger studied groups (140) 
Parameter agreeing Creatinine,INR, MELD Creatinine,INR, MELD 
Dissimilarity  APACHE-III being used Selective parameters of APACHE-
III used 
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                                                            Summary 
 
In order to study the causes of in-hospital mortality of DCLD patients and assess 
the association of in-hospital mortality to various demographic factors like 
hematological parameters, biochemical parameters and scores like CTP, MELD, 
MELD Sodium, this study was undertaken 
Patients with decompensated chronic liver disease who were admitted to the 
hospital were included in the study.  Patients with decompensated chronic liver 
disease who died during hospitalization were included in cases group while the 
patients with decompensated chronic liver disease who improved with treatment 
and were discharged were included in the control group. 
In both the cases and control groups, demographic parameters, biochemical 
parameters, hematological parameters and scores like CTP, MELD, MELD sodium 
were performed . 
The parameters of both cases and control groups were compared, matched and 
statistical analysis was performed. 
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The main causes of death were a result of complications resulting from hepatic 
insufficiency like hepatic encephalopathy and hepatorenal syndrome. Non hepatic 
insufficiency related cause of mortality was mainly due to intercurrent infections 
The results of my study showed that the duration of the underlying disease, 
hematological parameters like leukocytosis and neutrophilia, biochemical 
parameters like creatinine, INR, SGPT were significantly associated with 
mortality. While scores like MELD and MELD sodium are associated with in 
hospital mortality, Child’s score was not related to in-hospital mortality 
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                                                          Conclusion 
 
1.  In my study, Inhospital mortality in cirrhosis is predominantly due to 
hepatic dysfunction.  
2. The most common cause of mortality in decompensated cirrhosis is due to 
hepatic encephalopathy, hepato renal syndrome and upper gastro intestinal 
bleeding. 
3.  In my study -Intercurrent infections are associated with mortality and is the 
most common cause of mortality not related to hepatic decompensation in 
cirrhotic patients 
4. In my study--Longer duration of disease, high leukocyte count, high 
neutrophilia,  higher INR, high creatinine,   high SGPT  is associated with 
mortality. Patients who had died also exhibited higher MELD and MELD 
sodium value levels 
5. Therefore when patients are admitted with hepatic decompensation, clinical 
parameter like duration of disease, hematological parameters like leukocyte 
count  and neutrophilia, biochemical parameters like creatinine,  SGPT and 
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INR can help predict short term or in hospital mortality along with MELD 
and MELD sodium. 
6. In my study - Child score did not help in predicting short term mortality in 
hospitalized patients. 
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Proforma                                         
1. Name                                                                                                Cause of Death : 
 
2. Age/ DOB                                                                                         Duration of admission: 
 
3. Sex 
 
4.     MGE No 
5.  Blood group 
6.  Diagnosis  with etiology 
7.  Resident of:  Chennai / other city (specify) 
8. Type of house:  pucca/hut/semi 
9. Per capita income 
10. Literacy status:  studied up to: no education/I-V/VI-VIII/IX-XII/college/professional/other courses 
11. Occupation (as such) 
12. No. of children 
13. No. of adult family members 
14. Religion:  Hindu /Muslim /Christian/others (specify) 
15. Smoker: - present/past/never 
            If past: duration of smoking in yrs - <1/1-<5/5-<10/ > 10-<20/>20 Yrs 
                                                                Brand:- Beedi/Cigarette/combined 
                                                                Stopped when :- 
           If present: duration of smoking in yrs: <1/1-<5/5-<10/ > 10-<20/>20 Yrs 
                                                                   Brand:- Beedi/Cigarette/combined 
16. Alcohol:- present/past/never 
       17 . Dietetic history: - Veg / Non-veg 
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Clinical details: 
 
1. Cirrhosis grade 
2. Duration of illness ( as such):   
3. Age at diagnosis (as such): 
4.  Presence of acute exacerbations 
5. Jaundice                              :  Yes / No; if yes for how long…… 
6. Oedema legs & ascites      : Yes / No 
7.  Coagulopathy                    : Yes/No 
8. Hepato renal syndrome     : Yes/No 
9. GI Bleed                               : Yes/No 
10. Hepatic encephalopathy : Yes/No 
11. Weakness                              Yes / No 
12.  Hepatomegaly                     yes / No        Bruit:Yes/no 
13.  Splenomegaly           Yes / No        Fever: Yes/no 
14. Hepatic encephalopathy 
15.  Investigations: 
Date  
 TC  
Hb  
Platelets  
PCV  
PT  
APTT  
INR  
Urea  
Sugar F/PP  
Creatinine  
Na+  
K+  
Chloride  
Bicarbonate  
Bilirubin T  
Bilirubin B  
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Albumin  
Globulin  
AST  
ALT  
GGT  
S. Alk Phos  
Ca 2+ (I)  
S. AFP  
HBsAg  
Anti HCV  
MELD -Na  
MELD  
 
13. Ascitic fluid analysis 
14. UGI scopy: 
15. Liver biopsy: 
 
16. USG abdomen:     
Liver Shrunken/large/normal size 
 Echotexture:  coarse / normal 
 Edges:  regular/irregular 
 Nodularity:  yes / No 
PV Diameter:  9-12 mm ; > 12 mm 
 Direction of blood flow Hepatopetal 
 
Hepatofugal 
 
Spleen Size 
Ascites Present/absent  
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17.  CECT Abdomen:-              
Liver  
  
Spleen  
Ascites  
  
  
  
18. Treatment:-            
                      For liver disease: Yes/No    
Pharmacotherapy: 
 
Surgery: 
 
                      Combination: - Yes/No  
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                                                                Master chart 
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                         Cases
Serial No Name Age Sex Diagnosis Duration of disease Cause of death Hepatic complications No of non hepatic complications CHILD MELD MELD‐Na DF soc
1 Victor 51 1 Ethanol related DCLD 24 m HRS 2 0 C 31 33 54 LO
2 Siva Rao 41 1 Ethanol related DCLD 36 m HRS 2 0 C 48 46 238 LO
3 Prabukumar 35 1 Ethanol related DCLD 24m HE 2 0 C 24 31 82 LO
4 Bala Krishnan 53 1 Ethanol related DCLD 12m HRS/ SBP 3 0 C 29 29 74 LO
5 Jaya Prakash 36 1 Ethanol related DCLD 24 months HRS 2 0 B 33 34 28 Lo
6 Elumalai 35 1 Ethanol related DCLD 12 months HRS 2 0 C 36 38 84 LO
7 Suresh 35 1 Ethanol related DCLD 12 months HE 2 0 C 21 28 47 LO
8 Saravanan 38 1 Ethanol related DCLD 6 months HRS 2 0 C 35 37 68 Mi
9 Kesavan 58 1 Ethanol related DCLD 18 month Sepsis 1 1 B 22 22 34 LO
10 Nedunchelian 50 1 HBV related DCLD 24 months HRS 2 1 C 27 32 35 LO
11 Muthukrishnan 50 1 Cryptogenic DCLD 12 months HE 3 0 C 40 40 266 LO
12 Murugesan 43 1 Ethanol related DCLD 3 month HRS 3 0 C 38 39 159 mi
13 Shanmugam 43 1 Ethanol related DCLD 12 months HE 2 0 C 32 35 55 LO
14 Gajendran 53 1 Ethanol related DCLD 12 months HRS/ SBP 2 0 B 18 25 15 Hig
15 Ulaganathan 35 1 Ethanol related DCLD 24 months UGI bleed 4 0 C 43 42 135 Hig
16 Karuppusamy 45 1 Ethanol related DCLD 2 months HRS/ SBP 2 0 B 27 29 60 LO
17 Selvarani 40 2 Cryptogenic DCLD 6 months HRS 2 0 B 23 27 62 LO
18 Utharakumar 27 1 Ethanol related DCLD 36 months HE 3 0 C 22 22 27 LO
19 Sakthivel 41 1 HBV & Ethanol related DCLD 24 months HE 2 0 B 28 33 31 LO
20 Ilayabharati 38 1 Ethanol related DCLD 48 months UGI bleed 4 0 C 24 30 75 Mi
21 Sivan pillai 50 1 Ethanol related DCLD 24 months HRS 2 0 B 31 31 26 Hig
22 Parasuraman 45 1 HBV related DCLD 60 months HE 1 0 C 29 33 27 Mi
23 Srinivasan 18 1 Wilson disease related DCLD 12 months HE 2 0 C 29 31 142 Mi
24 Selvaraj 50 1 Ethanol related DCLD 48 months HRS 2 0 B 20 28 24 Mi
25 Santana krishnan 43 1 Ethanol related DCLD 6 months HRS/ SBP 4 0 C 26 28 44 LO
26 Dayalan 39 1 Ethanol related DCLD 6 months HE 3 0 C 28 33 81 LO
27 Azeemunisha 58 2 AI related DCLD 36 months HE 1 0 B 22 29 65 Mi
28 Govindasami 61 1 HBV related DCLD 24 months HRS 3 0 C 37 38 137 Mi
29 Parveenisha 27 2 Wilson disease related DCLD 4 months HE 2 0 C 28 33 158 LO
30 Datchayani 57 2 HBV related DCLD HE/  HRS HE 2 0 C 48 46 38 mi
31 Pradeep kumar 29 1 BCS related DCLD 18 months HE 2 0 B 11 22 38 Mi
32 Basha 60 1 Ethanol related DCLD 6 months HE 2 1 B 16 25 24 LO
33 Selvaraj 55 1 HBV related DCLD 12 months HE 3 0 B 11 22 20 LO
34 Thangam 73 2 Cryptogenic DCLD 48 months Sepsis 2 0 A 13 13 61 Up
35 Arul Mozhi 52 1 Ethanol related DCLD 12 months HE 2 0 B 12 23 34 Up
36 Rajasundar 41 1 HBV related DCLD 36 months HRS 2 0 B 27 32 54 Mi
37 Prem Kumar 47 1 HBV related DCLD 12 months HE 1 0 B 12 16 24 LO
38 Santama moorthi 43 1 Ethanol related DCLD 6 months HE 2 0 B 13 23 52 LO
39 Paranthaman 55 1 NAFLD related DCLD 24 months HE 3 0 B 20 28 65 Mi
40 Nelson 46 1 Ethanol related DCLD 6 months UGI bleed 2 0 B 18 25 22 LO
41 Krishnamoorthi 47 1 Ethanol related DCLD 6 months SBP 2 0 B 20 28 46 Up
42 Velu 50 1 Ethanol related DCLD 6 months HE 1 1 B 18 26 43 Mi
43 Bala Manoharan 55 1 Cryptogenic DCLD 24 months HE 2 0 B 20 21 44 Mi
44 Krishna Moorthy 59 1 Cryptogenic DCLD 12 months HE 2 0 B 15 24 40 Mi
45 Prasad 50 1 Ethanol related DCLD 6 months UGI bleed 1 0 A 10 21 11 LO
46 Lenin Joseph 15 1 Cryptogenic DCLD 12 months UGI bleed 2 0 B 21 28 39 LO
47 Elangovan 58 1 HBV related DCLD 48 months HE 3 0 B 26 31 22 LO
48 Prasanna Kumar 45 1 Ethanol related DCLD 60 months HRS 2 0 B 29 33 50 LO
49 Thirunavakarasu 63 1 HBV related DCLD 60 months Cellulitis leg 2 1 C 35 37 74 Mi
50 Muthukrishnan 42 1 Ethanol related DCLD 6 months UGI bleed 2 0 A 13 21 48 LO
51 Rajendran 52 1 Ethanol related DCLD 12 months UGI bleed 4 0 B 22 29 29 LO
52 Peter John 39 1 Ethanol related DCLD 12 months UGI bleed 3 0 A 7 19 24 LO
53 Kesavan 56 1 HBV & Ethanol related DCLD 12 months UGI bleed 1 0 A 13 23 19 Mi
54 Sachitanandam 62 1 Ethanol related DCLD 6 months UGI bleed 1 0 A 14 24 18 LO
55 Ashok Joshi 45 1 Ethanol related DCLD 6 months HE 2 1 B 20 26 31 Mi
56 Pandian 42 1 Ethanol related DCLD 6 months Sepsis 1 1 A 9 10 19 LO
57 Kumarapillai 56 1 Ethanol related DCLD 36 months Sepsis 2 0 B 18 26 26 LO
58 Rajeshwari 50 2 HCV related DCLD 24 months UGI bleed 1 1 A 9 20 6 Mi
59 Munusami 54 1 Ethanol related DCLD 6 months HE 1 1 B 17 26 33 LO
60 Gopala Krishnan 48 1 Ethanol related DCLD 24 months HRS 3 0 C 28 30 35 Mi
61 Ethirajulu 54 1 Ethanol related DCLD 24 months UGI bleed 2 0 B 28 33 66 LO
62 Parasuram  50 1 Ethanol related DCLD 36 months HRS 3 0 C 40 40 88 LO
63 Ponmarimuthu 38 1 Ethanol related DCLD 12 months Sepsis 3 1 C 29 33 69 Mi
64 Subramani 60 1 HBV & Ethanol related DCLD 48 months SBP 4 0 C 45 44 91 LO
65 Ashok Raj 43 1 Ethanol related DCLD 12 months HRS 3 1 C 40 40 111 LO
66 Sukumaran 45 1 Ethanol related DCLD 24 months Sepsis 2 0 B 25 31 20 LO
67 Vinayagam 35 1 HBV & Ethanol related DCLD 12 months UGI bleed 2 0 B 23 26 28 LO
68 Mani 60 1 Ethanol related DCLD 12 months Sepsis 1 1 B 20 27 33 LO
69 Bala Subramanian 38 1 Ethanol related DCLD 24 months HE 2 0 B 24 30 39 LO
70 Jeeva 36 1 HCV related DCLD 36 months HRS 4 0 C 23 25 35 Mi
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                                 Controls 
Serial No Name Age Sex Diagnosis Duration of disease Cause of admission Hepatic complications Non hepatic complications Child's MELD MELD Na DF socioe
1 Kali 48 1 HBV related DCLD 6 month UGI bleed 2 0 A 16 25 44 Lower
2 Kumaresan 41 1 Ethanol related DCLD 5 month SBP/ HRS 2 0 B 11 15 6 Lower
3 Kulothunga 34 1 Cryptogenic DCLD 36 months HE 3 2 B 18 22 50 Lower
4 Rajendran 50 1 Ethanol related DCLD 6 month HE 1 0 B 28 32 114 middle
5 Narayanan 36 1 Ethanol related DCLD 24 months HRS 3 0 C 27 28 61 middle
6 Barkatullah 35 1 Ethanol related DCLD 12 months HRS 3 0 C 18 26 24 Lower
7 Ganesan 37 1 Ethanol related DCLD 12 months HE 2 0 C 23 28 85 Lower
8 Kannan 36 1 Cryptogenic DCLD 48 months HE 2 0 B 12 23 25 Lower
9 Shanmuga 58 1 Ethanol related DCLD 9 month HE 1 1 B 15 21 37 middle
10 Manipallav 51 1 Ethanol related DCLD 6 month HE 2 0 C 15 24 32 Lower
11 Kailasam 49 1 Ethanol related DCLD 6 month HE 1 0 B 18 26 12 Lower
12 Abu bakka 43 1 Ethanol related DCLD 12 months Cellulitis leg 1 1 B 25 29 56 middle
13 Aravind 42 1 Ethanol related DCLD 12 months HE 4 0 C 19 25 63 middle
14 Durairaj 55 1 Ethanol related DCLD 6 month HRS 2 0 C 27 32 60 Lower
15 Ramakrish 34 1 HBV & Ethanol related DCLD6 month Cellulitis leg 1 1 B 17 22 19 middle
16 Valluvama 46 1 Ethanol related DCLD 12 months refractory ascites/ H. encephal 2 0 B 14 21 79 middle
17 Pandian 32 1 Ethanol related DCLD 6 month SBP 3 0 C 27 31 76 Lower
18 Krishnamo 27 1 Ethanol related DCLD 6 month HE 2 0 B 19 27 44 middle
19 Murali 41 1 Ethanol related DCLD 12 months HE 3 0 C 24 30 72 middle
20 Ganesan 37 1 Ethanol related DCLD 6 month SBP 3 0 B 18 19 21 Lower
21 Periyasam 48 1 Ethanol related DCLD 18 months HE 2 1 B 17 24 29 Lower
22 Purushotta 45 1 Ethanol related DCLD 6 month UGI bleed 2 0 B 23 26 37 middle
23 Balaji 18 1 Wilson disease 24 months HE 1 0 B 19 22 37 Lower
24 Etheraj 49 1 HBV related DCLD 6 month HE 2 0 B 16 20 22 Lower
25 Sakthi Vel 43 1 Cryptogenic DCLD 24 months HE 2 1 B 16 18 15 middle
26 Mani  42 1 Ethanol related DCLD 12 months UGI bleed 1 0 A 18 18 14 middle
27 Parimala 60 2 HBV related DCLD 6 month UGI bleed 1 1 A 9 18 20 Lower
28 Padmanab 62 1 Ethanol related DCLD 24 months HE 2 0 C  18 20 49 Lower
29 Kumar  25 1 Ethanol related DCLD 3 months UGI bleed 3 0 B 26 31 73 Lower
30 Kasthuri 56 2 Cryptogenic DCLD 12 months HE 1 0 C 12 23 33 middle
31 Selvam 30 1 Ethanol related DCLD 24 months Sepsis 1 1 B 27 30 109 Lower
32 Dhanapaul 60 1 Ethanol related DCLD 36 months UGI bleed 1 0 A 13 16 15 Lower
33 Jothi 55 1 HBV & Ethanol related DCLD6 month UGI bleed 1 0 A 8 8 15 Lower
34 Kathija Bee 73 2 NAFLD related DCLD 6 month HE 2 0 C 19 27 45 Lower
35 Venkatesa 50 1 Ethanol related DCLD 6 month HRS 1 1 B 25 31 29 middle
36 Anthony D 40 1 Ethanol related DCLD 12 months HE 2 0 B 12 23 15 Lower
37 Murugan 45 1 Ethanol related DCLD 12 months HE 1 1 B 11 22 19 Lower
38 Vijayan 44 1 Ethanol related DCLD 6 month HE 1 0 B 14 20 25 Lower
39 Venkata Su 56 1 NAFLD related DCLD 6 month HRS 3 1 C 26 31 51 Lower
40 Selva Pand 45 1 Ethanol related DCLD 6 month HRS 4 1 C 28 32 73 middle
41 Venkatesh 45 1 Ethanol related DCLD 48 months SBP 3 1 C 19 27 31 Lower
42 Sekar 50 1 Ethanol related DCLD 12 months HE 2 0 B 19 27 69 middle
43 Puniyakoti 55 1 HCV & Ethanol related DCLD6 month HE 2 1 C 20 22 49 Lower
44 Sundaram 61 1 Cryptogenic DCLD 6 month HE 2 1 B 11 22 7 middle
45 Annadurai 50 1 Cryptogenic DCLD 24 months UGI bleed 1 1 A 10 10 11 middle
46 George Fer 13 1 Wilson disease 36 months SBP 3 0 B 19 19 55 Lower
47 Anand 60 1 Ethanol related DCLD 6 month UGI bleed 2 0 A 9 20 7 Lower
48 Rama Subr 46 1 Cryptogenic DCLD 36 months Refractory Ascites  2 0 B 14 22 31 middle
49 Ramamoo 63 1 HBV related DCLD 6 month HE 1 0 B 18 26 55 Lower
50 Venkatesa 40 1 Ethanol related DCLD 24 months HE 2 0 B 18 26 30 Lower
51 Kotti 55 1 Ethanol related DCLD 12 months HE 1 0 B 23 29 35 Lower
52 Ravi 44 1 Ethanol related DCLD 6 month HRS 2 0 B 34 35 69 Lower
53 Aravind 53 1 Ethanol related DCLD 12 months SBP 2 0 C 23 29 86 Lower
54 Bala Nagar 64 1 HCV related DCLD/ PHT 12 months HE 1 0 B 12 14 34 middle
55 Rajendran 45 1 Ethanol related DCLD 6 month HE 1 0 C 20 20 75 Lower
56 Parthasara 44 1 Ethanol related DCLD 12 months HE 2 0 C 21 22 84 Lower
57 Murugesan 58 1 Ethanol related DCLD 6 month HRS 2 1 B 11 14 16 middle
58 Fathima Be 17 2 Cryptogenic DCLD 6 month HE 2 0 B 12 14 9 Lower
59 Krishnamo 47 1 Ethanol related DCLD 6 month SBP 2 0 C 20 28 42 middle
60 Pushparaj 45 1 HBV related DCLD 12 months HE 2 0 B 15 19 39 Lower
61 Gurusamy  45 1 Ethanol related DCLD 12 months HRS 3 0 C 23 29 38 Lower
62 Selvam 45 1 Ethanol related DCLD 6 month HRS 1 0 C 27 32 33 middle
63 Guna Seka 35 1 Ethanol related DCLD 6 month HE 2 0 C 23 26 71 middle
64 Balanagara 64 1 HCV related DCLD/ PHT 18 months SBP 1 0 B 16 21 44 Lower
65 Venkatesh 44 1 Ethanol related DCLD 12 months HE 2 1 C 27 29 121 Lower
66 Manisekar 45 1 Ethanol related DCLD 6 month SBP 2 0 B 17 26 45 middle
67 Alagu Sund 32 1 Ethanol related DCLD 6 month UGI bleed 1 0 B 15 24 31 Lower
68 Damodhar 70 1 HCV related DCLD/ PHT 6 month UGI bleed 1 1 A 7 7 15 Lower
69 Ramesh Ch 44 1 Ethanol related DCLD 18 months HE 3 0 C 19 24 40 middle
70 Murali 32 1 Ethanol related DCLD 6 month HE 3 1 C 18 19 47 middle
 
Serial No Name Age Sex Diagnosis Duration of disease Cause of death Hepatic complications No of non hepatic complications CHILD MELD MELD‐Na DF socioeconoplatelet TC NEUTROPHDC HemoglobiESR APTT PT INR
1 Victor 51 1 Ethanol related DCLD 24 m HRS 2 0 C 31 33 54 LOWER 94,000 8,800 93 93/03/04 9.9 38 36 24 1.8
2 Siva Rao 41 1 Ethanol related DCLD 36 m HRS 2 0 C 48 46 238 LOWER 1.81,000 15,300 81 81/12/07 8.8 24 32 60 4.6
3 Prabukumar 35 1 Ethanol related DCLD 24m HE 2 0 C 24 31 82 LOWER 132,000 21,000 81 81/09/10 12 46 34 26 1.9
4 Bala Krishnan 53 1 Ethanol related DCLD 12m HRS/ SBP 3 0 C 29 29 74 LOWER 202,000 41,700 92 92/02/06 7.6 45 34 29 2.2
5 Jaya Prakash 36 1 Ethanol related DCLD 24 months HRS 2 0 B 33 34 28 Lower 95,000 6900 67 67/23/10 6 84 24 18 2
6 Elumalai 35 1 Ethanol related DCLD 12 months HRS 2 0 C 36 38 84 LOWER 89,000 16,600 81 81/09/10 4.4 82 32 29 2.2
7 Suresh 35 1 Ethanol related DCLD 12 months HE 2 0 C 21 28 47 LOWER 2.21.000 27,000 87 87/06/07 6 60 32 20 1.5
8 Saravanan 38 1 Ethanol related DCLD 6 months HRS 2 0 C 35 37 68 Middle 91,000 14,400 85 85/09/06 8 62 34 26 1.9
9 Kesavan 58 1 Ethanol related DCLD 18 month Sepsis 1 1 B 22 22 34 LOWER 130,000 8,800 75 75/20/05 8 22 26 18 1.9
10 Nedunchelian 50 1 HBV related DCLD 24 months HRS 2 1 C 27 32 35 LOWER 100,000 10,800 70 70/30/0 10.2 15 50 18 1.7
11 Muthukrishnan 50 1 Cryptogenic DCLD 12 months HE 3 0 C 40 40 266 LOWER 65,000 13,200 78 78/20/2 5.2 40 60 70 5.8
12 Murugesan 43 1 Ethanol related DCLD 3 month HRS 3 0 C 38 39 159 middle 69,000 7,400 65 65/17/10/0 8.4 42 52 45 3.4
13 Shanmugam 43 1 Ethanol related DCLD 12 months HE 2 0 C 32 35 55 LOWER 100,000 4,200 60 60/38/2 8.2 25 43 23 2.2
14 Gajendran 53 1 Ethanol related DCLD 12 months HRS/ SBP 2 0 B 18 25 15 Higher 266,000 15,000 88 88/10/2 9.6 20 28 16 1.1
15 Ulaganathan 35 1 Ethanol related DCLD 24 months UGI bleed 4 0 C 43 42 135 Higher 64,000 38,700 85 85/9/6 10 40 51 38 2.8
16 Karuppusamy 45 1 Ethanol related DCLD 2 months HRS/ SBP 2 0 B 27 29 60 LOWER 69,000 19,800 86 86/8/6 8.1 36 54 24 1.8
17 Selvarani 40 2 Cryptogenic DCLD 6 months HRS 2 0 B 23 27 62 LOWER 168,000 25,800 90 90/8/2 8.9 34 38 23 1.7
18 Utharakumar 27 1 Ethanol related DCLD 36 months HE 3 0 C 22 22 27 LOWER 130,000 4,800 72 72/22/6 7.7 38 26 15 1.1
19 Sakthivel 41 1 HBV & Ethanol related DCLD 24 months HE 2 0 B 28 33 31 LOWER 101,000 8,900 69 69/30/1 8.4 24 32 18 1.7
20 Ilayabharati 38 1 Ethanol related DCLD 48 months UGI bleed 4 0 C 24 30 75 Middle 149,000 16,600 86 86/10/4 9.6 40 60 25 1.8
21 Sivan pillai 50 1 Ethanol related DCLD 24 months HRS 2 0 B 31 31 26 Higher 138,000 3,500 60 60/37/3 10.7 48 26 14 1
22 Parasuraman 45 1 HBV related DCLD 60 months HE 1 0 C 29 33 27 Middle 140,000 7,200 65 65/32/3 10 110 24 17 1.1
23 Srinivasan 18 1 Wilson disease related DCLD 12 months HE 2 0 C 29 31 142 Middle 22,000 12,700 81 81/17/2 5.9 52 62 41 3.1
24 Selvaraj 50 1 Ethanol related DCLD 48 months HRS 2 0 B 20 28 24 Middle 112,000 9,300 78 78/20/2 7.9 45 30 18 1.4
25 Santana krishnan 43 1 Ethanol related DCLD 6 months HRS/ SBP 4 0 C 26 28 44 LOWER 40,000 3,800 81 81/15/4 8.3 60 34 21 1.7
26 Dayalan 39 1 Ethanol related DCLD 6 months HE 3 0 C 28 33 81 LOWER 149,000 23,300 85 85/13/2 6.7 45 38 30 2.2
27 Azeemunisha 58 2 AI related DCLD 36 months HE 1 0 B 22 29 65 Middle 100,000 5,100 60 60/40/0 10.2 12 28 25 1.8
28 Govindasami 61 1 HBV related DCLD 24 months HRS 3 0 C 37 38 137 Middle 47,000 5,100 80 80/10/10 10 45 54 42 3.1
29 Parveenisha 27 2 Wilson disease related DCLD 4 months HE 2 0 C 28 33 158 LOWER 98,000 10,900 75 75/15/10 6.2 12 44 46 3.6
30 Datchayani 57 2 HBV related DCLD HE/  HRS HE 2 0 C 48 46 38 middle 88,000 4,600 71 71/19/10 6.5 72 32 21 1.6
31 Pradeep kumar 29 1 BCS related DCLD 18 months HE 2 0 B 11 22 38 Middle 2.48,000 10,800 90 90/02/08 12 36 32 21 1.5
32 Basha 60 1 Ethanol related DCLD 6 months HE 2 1 B 16 25 24 LOWER 120,000 8,200 60 60/36/4 11.2 15 28 17 1.3
33 Selvaraj 55 1 HBV related DCLD 12 months HE 3 0 B 11 22 20 LOWER 90,000 5,500 68 68/16/12 5.5 120 26 17 1.2
34 Thangam 73 2 Cryptogenic DCLD 48 months Sepsis 2 0 A 13 13 61 Upper 108,000 15,200 62 62/28/10 11.2 55 32 26 1.6
35 Arul Mozhi 52 1 Ethanol related DCLD 12 months HE 2 0 B 12 23 34 Upper 83,000 5,500 74 74/16/10 8.7 24 34 20 1.4
36 Rajasundar 41 1 HBV related DCLD 36 months HRS 2 0 B 27 32 54 Middle 56,000 2,100 66 66/28/3 13.5 22 31 24 1.6
37 Prem Kumar 47 1 HBV related DCLD 12 months HE 1 0 B 12 16 24 LOWER 84,000 6,400 85 85/9/6 12.6 15 28 18 1.3
38 Santama moorthi 43 1 Ethanol related DCLD 6 months HE 2 0 B 13 23 52 LOWER 52,000 5,100 55 55/30/10 7.8 24 36 24 1.6
39 Paranthaman 55 1 NAFLD related DCLD 24 months HE 3 0 B 20 28 65 Middle 78,000 14,400 86 86/10/4 11 42 36 26 1.9
40 Nelson 46 1 Ethanol related DCLD 6 months UGI bleed 2 0 B 18 25 22 LOWER 151,000 6,800 65 65/27/8 10.9 15 30 17 1.9
41 Krishnamoorthi 47 1 Ethanol related DCLD 6 months SBP 2 0 B 20 28 46 Upper 57,000 1,700 80 80/19/1 9 16 30 20 1.4
42 Velu 50 1 Ethanol related DCLD 6 months HE 1 1 B 18 26 43 Middle 55,000 5,200 76 76/17/7 11.6 14 30 21 1.5
43 Bala Manoharan 55 1 Cryptogenic DCLD 24 months HE 2 0 B 20 21 44 Middle 36,000 3,800 73 73/24/3 10.8 84 30 20 1.5
44 Krishna Moorthy 59 1 Cryptogenic DCLD 12 months HE 2 0 B 15 24 40 Middle 48,000 5,000 64 64/30/6 9.2 32 32 21 1.5
45 Prasad 50 1 Ethanol related DCLD 6 months UGI bleed 1 0 A 10 21 11 LOWER 100,000 5,700 70 70/24/6 10 12 28 15 1.2
46 Lenin Joseph 15 1 Cryptogenic DCLD 12 months UGI bleed 2 0 B 21 28 39 LOWER 74,000 5,000 82 82/15/3 8.6 15 32 18 1.4
47 Elangovan 58 1 HBV related DCLD 48 months HE 3 0 B 26 31 22 LOWER 168,000 7,000 88 88/10/2 12.5 48 28 16 1.2
48 Prasanna Kumar 45 1 Ethanol related DCLD 60 months HRS 2 0 B 29 33 50 LOWER 159,000 7,800 84 84/13/3 7.1 110 34 22 1.5
49 Thirunavakarasu 63 1 HBV related DCLD 60 months Cellulitis leg 2 1 C 35 37 74 Middle 136,000 12,900 85 85/10/5 7.6 122 56 24 1.9
50 Muthukrishnan 42 1 Ethanol related DCLD 6 months UGI bleed 2 0 A 13 21 48 LOWER 67,000 9,100 86 86/9/5 10.3 247 34 23 1.6
51 Rajendran 52 1 Ethanol related DCLD 12 months UGI bleed 4 0 B 22 29 29 LOWER 65,000 12,000 82 82/10/8 6.5 122 41 19 2.1
52 Peter John 39 1 Ethanol related DCLD 12 months UGI bleed 3 0 A 7 19 24 LOWER 100,000 9,300 63 63/32/3 9.4 78 26 18 1.1
53 Kesavan 56 1 HBV & Ethanol related DCLD 12 months UGI bleed 1 0 A 13 23 19 Middle 220,000 18,100 52 52/42/6 8.3 40 26 17 1.8
54 Sachitanandam 62 1 Ethanol related DCLD 6 months UGI bleed 1 0 A 14 24 18 LOWER 186,000 7,300 52 52/46/2 7.2 15 27 16 1.2
55 Ashok Joshi 45 1 Ethanol related DCLD 6 months HE 2 1 B 20 26 31 Middle 57,000 14,400 85 85/7/8 8.9 50 31 18 1.3
56 Pandian 42 1 Ethanol related DCLD 6 months Sepsis 1 1 A 9 10 19 LOWER 105,000 6,800 60 60/30/10 11.6 50 30 17 1.3
57 Kumarapillai 56 1 Ethanol related DCLD 36 months Sepsis 2 0 B 18 26 26 LOWER 42,000 9,200 64 64/32/4 7.5 85 28 17 1.4
58 Rajeshwari 50 2 HCV related DCLD 24 months UGI bleed 1 1 A 9 20 6 Middle 188,000 7,900 60 60/34/6 6.1 24 28 14 1.3
59 Munusami 54 1 Ethanol related DCLD 6 months HE 1 1 B 17 26 33 LOWER 45,000 6,800 52 52/36/12 7.7 26 29 19 1.3
60 Gopala Krishnan 48 1 Ethanol related DCLD 24 months HRS 3 0 C 28 30 35 Middle 98,000 7,800 70 70/28/2 9.4 32 30 19 1.5
61 Ethirajulu 54 1 Ethanol related DCLD 24 months UGI bleed 2 0 B 28 33 66 LOWER 74,000 12,300 78 78/12/10 7.8 115 32 21 1.7
62 Parasuram  50 1 Ethanol related DCLD 36 months HRS 3 0 C 40 40 88 LOWER 83,000 14,200 80 80/12/8 6.2 42 34 26 2
63 Ponmarimuthu 38 1 Ethanol related DCLD 12 months Sepsis 3 1 C 29 33 69 Middle 126,000 17,800 80 80/11/9 11.1 45 30 22 1.6
64 Subramani 60 1 HBV & Ethanol related DCLD 48 months SBP 4 0 C 45 44 91 LOWER 65,000 11,300 84 84/12/4 9.1 62 36 29 3.8
65 Ashok Raj 43 1 Ethanol related DCLD 12 months HRS 3 1 C 40 40 111 LOWER 116,000 11,200 78 78/14/8 10.7 16 34 31 3.8
66 Sukumaran 45 1 Ethanol related DCLD 24 months Sepsis 2 0 B 25 31 20 LOWER 110,000 35,100 85 85/7/8 11.2 48 28 15 1.3
67 Vinayagam 35 1 HBV & Ethanol related DCLD 12 months UGI bleed 2 0 B 23 26 28 LOWER 85,000 7,000 55 55/45 10.8 110 30 17 1.6
68 Mani 60 1 Ethanol related DCLD 12 months Sepsis 1 1 B 20 27 33 LOWER 405,000 27,300 96 96/2/2 11.6 38 28 16 1.3
69 Bala Subramanian 38 1 Ethanol related DCLD 24 months HE 2 0 B 24 30 39 LOWER 63,000 11,200 82 82/12/6 9.2 12 28 18 1.4
70 Jeeva 36 1 HCV related DCLD 36 months HRS 4 0 C 23 25 35 Middle 61,000 15,000 67 67/24/9 8.6 30 32 20 1.6
Sugar Urea Creat T. Bil D.Bil SGOT SGPT SAP GGT T.Protein Albumin Globulin Sodium Potassium HIV HBsAg Anti HCV complications Others
74 127.2 3.79 3.8 1.55 68 25 266 35 4.5 2.3 2.2 130.4 5.11 NEG NEG NEG ascites / HRS/ ENC
65 139.6 11.74 21.5 19.3 83 27 414 112 6.3 2 4.3 128 3.65 NEG NEG NEG HRS/ HE
81 35.3 0.7 22.5 19.1 337 172 332 58 6.7 3 3.7 112.4 5.47 NEG NEG NEG UGI bleed/ascites
29 98.4 4.3 1.5 0.8 44 16 285 3 6.1 1.5 4.6 177.3 7.59 NEG NEG NEG Ascites/ HE
70 106.67 4.8 4.5 3.3 52 45 132 21 5.2 2.2 3 132 3.7 NEG NEG NEG Rec Encephalopathy/ HRS
74 66.86 3.37 10.49 6.6 752 161 170 30 5.4 2 3.4 118.5 4.91 NEG NEG NEG Ascites/ HE
101 51.68 0.86 14.3 10.5 173 98 272 100 5 2.1 2.9 122.5 3.33 NEG NEG NEG Bleeder
75 96.4 4.2 8.2 5.8 123 87 220 60 5.6 2.2 3.4 114 5.2 NEG NEG NEG HE
161 59 2.7 10.6 6.3 87 26 190 60 7.3 1.8 5.5 138 4.62 NEG NEG NEG cellulitis leg/ RF cellulitis leg
172 88 1.7 116 4.6 392 211 66 24 6.9 3.1 3.8 116 4.6 NEG POS NEG HE DM
60 38 1.3 4 2.1 140 132 210 42 5 1.8 3.2 120 4.5 NEG NEG NEG coagulopathy/ bleeder
262 147.24 2.4 11.5 8.9 255 156 336 53 6.7 1.5 5.2 118.9 5.05 NEG NEG NEG HE/ HRS/ Coag
170 78 1.6 8.6 4.2 142 72 132 24 5.8 3.9 1.9 95 3.7 NEG NEG NEG Ascites/ bleeder
108 91.5 3 0.9 0.5 51 23 151 45 5.6 2.4 3.2 127 4.6 NEG NEG NEG Ascites
120 115 7 20.4 16.8 161 153 237 123 4.9 2.4 2.5 121 3.6 NEG NEG NEG coagulopathy/ HRS/encephalopathy
58 90.67 1.68 9.6 5.3 125 65 255 10 6 2 4 135.3 5.4 NEG NEG NEG Ascites
169 26 0.4 15.5 12.77 36 39 284 40 4.8 2.4 2.4 131.6 3.06 NEG NEG NEG Refractory ascites
119 62.4 1.5 17.4 11.3 146 117 113 54 5.3 1.4 3.9 139 5.54 NEG NEG NEG Ascites/ bleeder/ HRS
55 99 2.1 8.4 5.5 92 38 199 30 6.8 2 4.8 118 5.6 NEG POS NEG HRS / ascites
118 44.9 0.7 20.01 11.09 147 51 259 120 6.8 3 3.8 124 5.4 NEG NEG NEG SBP/ ascites/ coagulopathy
146 115 4.2 21.6 14 38 102 387 43 5 2.3 2.7 148 1.83 NEG NEG NEG ascites
78 52 1.5 8.6 5.2 160 75 260 40 4.9 2.2 2.7 115 4.5 NEG POS NEG ascites
118 22.5 0.43 13.3 5.6 63 29 142 30 5.1 2 3.1 131 5.4 NEG NEG NEG Ascites/ coagulopathy
142 108.3 1.6 1 0.7 59 34 39 3 7 2.7 4.3 111.5 4.7 NEG NEG NEG Ascites/ hepatic hydrothorax
122 58 1.9 7 5 90 70 200 56 5.3 1.9 3.4 135 4.5 NEG NEG NEG Ascites/ HE/ Coagulopathy
94 53.1 2.4 2.8 1.6 99 37 352 92 6.5 2 4.5 141 2.4 NEG NEG NEG Ascites/ coagulopathy/ HRS
44 15 0.6 10.2 4.6 112 48 220 24 5.9 3 2.9 118 5.6 NEG NEG NEG Ascites
115 62 4.1 3.6 1.2 50 50 141 24 5.2 2.6 2.6 115 2.4 NEG NEG NEG HE/ Coagulopathy/ Ascites
88 27 0.7 6.2 4.5 352 141 295 34 5.1 2 3.1 122 4.4 NEG NEG NEG Ascites/ Coagulopathy
202 100.31 2.93 1.11 0.5 35 19 306 28 6.5 3 3.5 128.7 3.83 NEG POS NEG HRS
102 28.66 0.94 1 0.4 81 30 641 165 4 1.4 2.6 118.3 4.89 NEG NEG NEG refractory ascites
165 18 0.7 5.8 2.2 78 34 100 52 6 1.9 4.1 98 7 NEG NEG NEG Bleeder CAD
77 34.6 1.1 1.4 1.2 254 124 692 142 6.1 2.2 3.9 115 2.9 NEG NEG NEG refractory ascites /ugi bleed
124 143 1.18 0.7 0.2 76 60 237 4 4.4 2.4 2 151.2 4.98 NEG NEG NEG refractory ascites /ugi bleed
109 31.4 1.01 1.4 0.9 58 25 283 15 5 2.2 2.8 118 4.2 NEG NEG NEG refractory ascites
107 45.4 3.2 3.2 2.1 78 50 145 15 7.2 3.2 4 116 5.4 NEG POS NEG refractory ascites
134 25.65 1.34 0.5 0.2 166 50 231 24 4.8 2.5 2.3 135 4.4 NEG POS NEG Ascites
83 18 0.97 1.5 0.8 86 40 384 32 6.3 2 4.3 124 4.8 NEG NEG NEG Ascites/ Coagulopathy
432 27.99 0.7 5.2 3.2 64 38 310 30 6.6 2.8 3.8 110 2.4 NEG NEG NEG SBP/ ascites/ coagulopathy DM
88 15.12 0.46 3.1 1.9 71 33 71 14 7.7 3 4.7 128 3.6 NEG NEG NEG Ascites/ Coagulopathy
60 23.3 0.7 14.1 9.2 114 52 354 20 7.5 2.8 4.7 119 5.2 NEG NEG NEG Ascites/ HE
315 22.16 0.8 6.4 4.4 81 41 413 17 7.9 2.6 5.3 122 4.5 NEG NEG NEG Ascites DM
81 21.19 0.59 11.7 9.2 56 31 392 26 6.4 3.1 3.3 137.7 5.22 NEG NEG NEG refractory ascites
161 71 0.9 2.8 1 107 100 192 18 6 2.5 3.5 121 5.8 NEG NEG NEG Ascites/ coagulopathy
98 18 0.5 1.5 0.6 48 56 256 16 6.9 3.3 3.6 122 5.3 NEG NEG NEG Recurrent bleed
140 15 0.3 15.7 9.5 62 29 415 137 5.6 2 3.6 112 3.2 NEG NEG NEG Refractory ascites/ recurrent GI Bleed
91.7 76 2.9 7.7 6.2 302 88 341 46 5.3 2.1 3.2 110 4.9 NEG POS NEG Refractory ascites/ HRS
100 65 2.8 8.7 6.5 96 73 237 15 6.8 1.8 5 127 5.8 NEG NEG NEG Refractory ascites
74 127 2.6 23.3 18 210 106 541 353 6.3 2 4.3 114 5.2 NEG POS NEG HRS/ Coagulopathy/ Ascites DM
247 39.3 0.71 1.5 1 100 52 179 12 7.3 2.7 4.6 128 4.5 NEG NEG NEG Ascites/ Coagulopathy
112 68 2.1 1.1 0.6 217 67 617 28 6.1 3.1 2.6 114 4.8 NEG NEG NEG HRS/ HE /Coagulopathy
132 53 0.8 0.9 0.6 31 23 415 24 5.4 2.4 3 120 5.2 NEG NEG NEG HE/SBP
231 32 1 1 0.8 32 26 218 14 6.2 2.8 3.4 116 3.2 NEG POS NEG Recurrent bleed
121 26 0.9 4 2.4 121 86 256 32 5.6 2.4 3.2 116 4.5 NEG NEG NEG Recurrent bleed
111 49.62 1.4 7.8 6 42 24 178 24 5 2.1 2.9 129 4.4 NEG NEG NEG Recurrent bleed UTI
189 12.97 0.8 1.02 0.81 132 89 169 45 7.5 2.9 4.6 139 4.5 NEG NEG NEG HE DM
129 34 1 8 5 133 70 245 40 7.5 3 4.5 115 5.6 NEG NEG NEG Recurrent bleed/ HE
240 64 0.9 0.9 0.6 47 38 50 82 4.8 2.4 2.4 126 3.2 NEG NEG POS Recurrent bleed DM
111 58.3 1.1 5.2 2.1 302 88 181 12 6.3 1.4 4.9 120 4.2 NEG NEG NEG Recurrent encephalopathy DM
110 121 2.9 6.9 4 45 29 115 16 4.9 2 2.9 134 4.6 NEG NEG NEG Refractory ascites/ UGI bleed
156 54 1.3 29 23 88 64 212 36 4.8 2.1 2.7 116 4.8 NEG NEG NEG HE
66 112 6.4 28.4 20.3 84 66 256 110 7.1 2 5.1 110 3.2 NEG NEG NEG HE/ Coagulopathy/ Ascites
58 58 1.6 28 15.4 75 66 315 62 7 2.3 4.7 122 4.2 NEG NEG NEG HE/ HRS/Coagulopathy old PT
144 53.2 3.76 17.4 15.1 198 181 296 24 5.1 2 3.1 133 3.6 NEG POS NEG HE/ HRS/Coagulopathy
68 49 1.9 28 25 109 182 260 12 4.8 2 2.8 124 1.6 NEG NEG NEG HE/ Coagulopathy/ Ascites BA
98 75 2 10.6 8.4 92 56 254 12 5.2 2 3.2 122 3.6 NEG NEG NEG HRS/ UGI bleed
78 72 1.3 9.6 5.4 117 98 312 62 7.2 2.4 4.8 134 4.2 NEG POS NEG HE
93 40.12 0.17 18.7 16.6 100 71 534 180 4.9 2.2 2.7 126 5.4 NEG NEG NEG HE PT
75 56 1.4 16.2 12 152 76 258 46 5.2 2.2 3 118 4.5 NEG NEG NEG Refractory ascites
147 96.76 2.18 3 1.1 71 24 189 9 5.2 1 4.2 134.7 5.38 NEG NEG POS HE/ Coagulopathy/ hydrothorax
Serial No Name Age Sex Diagnosis Duration of disease Cause of admission Hepatic complications Non hepatic complications Child's MELD MELD Na DF socioeconomic platelet TC NEUTROPHILLS DC Hemoglobin
1 Kali 48 1 HBV related DCLD 6 month UGI bleed 2 0 A 16 25 44 Lower 94,000 6,600 59 59/31/10 10.9
2 Kumaresan 41 1 Ethanol related DCLD 5 month SBP/ HRS 2 0 B 11 15 6 Lower 205,000 17,300 70 70/22/08 5.7
3 Kulothunga 34 1 Cryptogenic DCLD 36 months HE 3 2 B 18 22 50 Lower 170,000 1,600 66 66/27/07 7.8
4 Rajendran 50 1 Ethanol related DCLD 6 month HE 1 0 B 28 32 114 middle 100,000 9,000 68 68/28/4 9
5 Narayanan 36 1 Ethanol related DCLD 24 months HRS 3 0 C 27 28 61 middle 78,000 4,200 58 58/41/1 9.7
6 Barkatullah 35 1 Ethanol related DCLD 12 months HRS 3 0 C 18 26 24 Lower 562,000 9,800 64 64/31/5 6.5
7 Ganesan 37 1 Ethanol related DCLD 12 months HE 2 0 C 23 28 85 Lower 69,000 7,300 78 78/19/3 9.8
8 Kannan 36 1 Cryptogenic DCLD 48 months HE 2 0 B 12 23 25 Lower 50,000 3,000 62 62/31/7 11.1
9 Shanmugam 58 1 Ethanol related DCLD 9 month HE 1 1 B 15 21 37 middle 200,000 9,500 78 78/12/10 9.9
10 Manipallav 51 1 Ethanol related DCLD 6 month HE 2 0 C 15 24 32 Lower 62,000 6,100 57 57/38/1 8.7
11 Kailasam 49 1 Ethanol related DCLD 6 month HE 1 0 B 18 26 12 Lower 120,000 8,700 64 64/33/3 11.2
12 Abu bakkar 43 1 Ethanol related DCLD 12 months Cellulitis leg 1 1 B 25 29 56 middle 113,000 27,800 86 86/06/08 7.8
13 Aravind 42 1 Ethanol related DCLD 12 months HE 4 0 C 19 25 63 middle 150,000 5,900 69 69/39/2 5.5
14 Durairaj 55 1 Ethanol related DCLD 6 month HRS 2 0 C 27 32 60 Lower 153,000 10,900 87 87/8/5 6.88
15 Ramakrishn 34 1 HBV & Ethanol related DCLD 6 month Cellulitis leg 1 1 B 17 22 19 middle 45,000 17,700 79 79/12/9 10.2
16 Valluvaman 46 1 Ethanol related DCLD 12 months refractory ascites/ H. encephal 2 0 B 14 21 79 middle 120,000 6800 66 66/32/2 10.2
17 Pandian 32 1 Ethanol related DCLD 6 month SBP 3 0 C 27 31 76 Lower 110,000 9,800 80 80/16/4 9
18 Krishnamoo 27 1 Ethanol related DCLD 6 month HE 2 0 B 19 27 44 middle 183,000 13,000 80 80/10/10 8.9
19 Murali 41 1 Ethanol related DCLD 12 months HE 3 0 C 24 30 72 middle 95,000 12,600 78 78/13/9 7.3
20 Ganesan 37 1 Ethanol related DCLD 6 month SBP 3 0 B 18 19 21 Lower 92,000 5,900 69 69/21/10 6.5
21 Periyasami 48 1 Ethanol related DCLD 18 months HE 2 1 B 17 24 29 Lower 90,000 7,000 84 84/6/10 8.6
22 Purushotta 45 1 Ethanol related DCLD 6 month UGI bleed 2 0 B 23 26 37 middle 178,000 13,000 85 85/10/05 10.6
23 Balaji 18 1 Wilson disease 24 months HE 1 0 B 19 22 37 Lower 120,000 10,200 70 70/30 9
24 Etheraj 49 1 HBV related DCLD 6 month HE 2 0 B 16 20 22 Lower 77,000 7,300 60 60/25/14 9.6
25 Sakthi Vel 43 1 Cryptogenic DCLD 24 months HE 2 1 B 16 18 15 middle 81,000 3,200 68 68/23/9 6.4
26 Mani  42 1 Ethanol related DCLD 12 months UGI bleed 1 0 A 18 18 14 middle 180,000 5,500 65 65/20/10 7.4
27 Parimala 60 2 HBV related DCLD 6 month UGI bleed 1 1 A 9 18 20 Lower 255,000 6,900 67 67/20/13 9.2
28 Padmanabh 62 1 Ethanol related DCLD 24 months HE 2 0 C  18 20 49 Lower 106,000 10,300 84 84/7/9 7.5
29 Kumar  25 1 Ethanol related DCLD 3 months UGI bleed 3 0 B 26 31 73 Lower 85,000 11,900 80 80/14/6 11.4
30 Kasthuri 56 2 Cryptogenic DCLD 12 months HE 1 0 C 12 23 33 middle 207,000 4,200 58 58/35/7 7.3
31 Selvam 30 1 Ethanol related DCLD 24 months Sepsis 1 1 B 27 30 109 Lower 65,000 11,900 64 64/30/6 4
32 Dhanapaul 60 1 Ethanol related DCLD 36 months UGI bleed 1 0 A 13 16 15 Lower 192,000 8,400 69 69/26/5 14
33 Jothi 55 1 HBV & Ethanol related DCLD 6 month UGI bleed 1 0 A 8 8 15 Lower 57,000 2,500 57 57/33/20 10.5
34 Kathija Bee 73 2 NAFLD related DCLD 6 month HE 2 0 C 19 27 45 Lower 34,000 5,100 50 50/40/10 7.2
35 Venkatesan 50 1 Ethanol related DCLD 6 month HRS 1 1 B 25 31 29 middle 317,000 8,400 66 66/24/10 7.4
36 Anthony Da 40 1 Ethanol related DCLD 12 months HE 2 0 B 12 23 15 Lower 43,000 13 77 77/13/10 11
37 Murugan 45 1 Ethanol related DCLD 12 months HE 1 1 B 11 22 19 Lower 75,000 8,000 83 83/09/08 4.8
38 Vijayan 44 1 Ethanol related DCLD 6 month HE 1 0 B 14 20 25 Lower 292,000 10,100 72 72/18/10 6.6
39 Venkata Su 56 1 NAFLD related DCLD 6 month HRS 3 1 C 26 31 51 Lower 77,000 15,600 82 82/12/6 6.3
40 Selva Pandi 45 1 Ethanol related DCLD 6 month HRS 4 1 C 28 32 73 middle 78,000 14,400 73 73/17/10 5.9
41 Venkatesh 45 1 Ethanol related DCLD 48 months SBP 3 1 C 19 27 31 Lower 76,000 3,900 68 68/23/9 6.6
42 Sekar 50 1 Ethanol related DCLD 12 months HE 2 0 B 19 27 69 middle 79,000 3,700 50 50/30/10 7.6
43 Puniyakoti 55 1 HCV & Ethanol related DCLD 6 month HE 2 1 C 20 22 49 Lower 25,000 3,300 75 75/15/10 8.5
44 Sundaram 61 1 Cryptogenic DCLD 6 month HE 2 1 B 11 22 7 middle 93,000 9,200 81 81/9/10 10.18
45 Annadurai 50 1 Cryptogenic DCLD 24 months UGI bleed 1 1 A 10 10 11 middle 57,000 6,500 70 70/28/2 10.3
46 George Fer 13 1 Wilson disease 36 months SBP 3 0 B 19 19 55 Lower 65,000 6,800 82 82/12/3 11
47 Anand 60 1 Ethanol related DCLD 6 month UGI bleed 2 0 A 9 20 7 Lower 58,000 3,600 86 86/13/1 6.3
48 Rama Subra 46 1 Cryptogenic DCLD 36 months Refractory Ascites  2 0 B 14 22 31 middle 70,000 4,000 63 63/34/3 12.8
49 Ramamoor 63 1 HBV related DCLD 6 month HE 1 0 B 18 26 55 Lower 110,000 9,800 64 64/32/4 11.4
50 Venkatesan 40 1 Ethanol related DCLD 24 months HE 2 0 B 18 26 30 Lower 42,000 6,400 72 72/18/10 6.1
51 Kotti 55 1 Ethanol related DCLD 12 months HE 1 0 B 23 29 35 Lower 138,000 8,600 42 42/48/10 10.3
52 Ravi 44 1 Ethanol related DCLD 6 month HRS 2 0 B 34 35 69 Lower 80,000 4,500 70 70/20/10 9.78
53 Aravind 53 1 Ethanol related DCLD 12 months SBP 2 0 C 23 29 86 Lower 176,000 11 80 80/10/10 7
54 Bala Nagara 64 1 HCV related DCLD/ PHT 12 months HE 1 0 B 12 14 34 middle 18,000 2,100 60 60/30/10 7.4
55 Rajendran 45 1 Ethanol related DCLD 6 month HE 1 0 C 20 20 75 Lower 170,000 7,300 74 74/9/9 12.2
56 Parthasarat 44 1 Ethanol related DCLD 12 months HE 2 0 C 21 22 84 Lower 36,000 4,000 60 60/32/8 11.2
57 Murugesan 58 1 Ethanol related DCLD 6 month HRS 2 1 B 11 14 16 middle 218,000 14,800 79 79/14/6 10.3
58 Fathima Be 17 2 Cryptogenic DCLD 6 month HE 2 0 B 12 14 9 Lower 573,000 13,200 65 65/28/07 7.9
59 Krishnamoo 47 1 Ethanol related DCLD 6 month SBP 2 0 C 20 28 42 middle 57,000 1,700 80 80/19/1 9
60 Pushparaj 45 1 HBV related DCLD 12 months HE 2 0 B 15 19 39 Lower 110,000 3,900 60 60/30/10 5.5
61 Gurusamy  45 1 Ethanol related DCLD 12 months HRS 3 0 C 23 29 38 Lower 120,000 5,300 70 70/26/4 7.5
62 Selvam 45 1 Ethanol related DCLD 6 month HRS 1 0 C 27 32 33 middle 50,000 8,000 75 75/15/10 11
63 Guna Sekar 35 1 Ethanol related DCLD 6 month HE 2 0 C 23 26 71 middle 160,000 18,100 80 80/10/10 6.8
64 Balanagara 64 1 HCV related DCLD/ PHT 18 months SBP 1 0 B 16 21 44 Lower 17,000 4,800 84 84/08/08 8.2
65 Venkatesh 44 1 Ethanol related DCLD 12 months HE 2 1 C 27 29 121 Lower 97,000 4,600 45 45/45/10 6.7
66 Manisekara 45 1 Ethanol related DCLD 6 month SBP 2 0 B 17 26 45 middle 75,000 9,700 70 70/20/10 9.6
67 Alagu Sund 32 1 Ethanol related DCLD 6 month UGI bleed 1 0 B 15 24 31 Lower 90,000 6,500 67 67/8/10 6.7
68 Damodhara 70 1 HCV related DCLD/ PHT 6 month UGI bleed 1 1 A 7 7 15 Lower 39,000 2,400 61 61/32/07 10
69 Ramesh Ch 44 1 Ethanol related DCLD 18 months HE 3 0 C 19 24 40 middle 171,000 6,700 60 60/31/9 10.9
70 Murali 32 1 Ethanol related DCLD 6 month HE 3 1 C 18 19 47 middle 221,000 31,100 74 74/18/08 9.1
ESR APTT PT INR Sugar Urea Creat T. Bil D.Bil SGOT SGPT SAP GGT T.Protein Albumin Globulin Sodium Potassium HIV HBsAg Anti HCV HE HRS Coag refractory aSBP Bleed Others
16 34 22 1.6 134 33.4 0.65 3 2.1 123 103 116 22 6.4 2 4.4 120 5 NEG POS NEG No No Yes No Yes
66 26 14 1 158 108.15 1.66 1 0.6 70 48 120 36 5.8 2 3.8 133.8 3.64 NEG NEG NEG
82 26 23 1.7 210 16.53 0.6 4.3 2.5 57 37 496 47 5.5 2.1 3.4 132 5.2 NEG NEG NEG Yes No Yes No No Yes DM/CAD
20 36 34 2.6 110 26 0.6 17.8 8.1 42 19 146 140 6.1 2 4.1 125.2 4.33 NEG NEG NEG
22 75 25.7 2.4 112 47 2.2 2.6 1.5 87 84 119 76 8.2 4 4.2 137 3.8 NEG NEG NEG No Yes Yes No No Yes
120 29 16 1.3 77 21.92 0.73 10.6 7.3 79 38 549 139 6.3 2.2 4.1 122 5.2 NEG NEG NEG Yes Yes No No No Yes
42 34 30 2.3 120 46.5 0.92 6.9 4.2 85 35 203 15 4.9 2 2.9 128 4.4 NEG NEG NEG Yes No Yes No No No
14 26 18 1.2 105 11 1.2 1.7 0.6 50 17 143 38 6.7 2.6 4.1 124 3.6 NEG NEG NEG Yes No No No No Yes
12 32 19 1 227 14.53 0.41 9.2 6.7 132 38 782 700 4.3 2.3 2 130 4.2 NEG NEG NEG Yes No No No No No DM 
15 30 19 1.3 138 20.2 0.49 4.6 2.8 52 25 326 18 5.9 2.9 3 119 5.2 NEG NEG NEG Yes No No No No Yes
12 30 12 1.2 96 25.02 0.5 12.35 9.3 171 71 358 42 6.1 2.2 3.9 122.2 5.73 NEG NEG NEG
62 32 24 1.7 107 80 1.89 5.2 3.4 87 39 174 20 6.2 2 4.2 130.6 4.52 NEG NEG NEG
20 56.3 26 1.6 94 45 1.5 2.7 1.5 76 60 225 40 5.5 3.2 3.3 128 4.2 NEG NEG NEG Yes Yes Yes No No Yes
20 32 23 1.7 95 25.8 1.7 13.5 10.5 161 146 364 18 6.5 2 4.5 120.2 5.4 NEG NEG NEG No Yes Yes No No No
98 26 14 1 49 41.3 0.34 14.5 11.2 117 46 361 68 4.8 1.8 3 132 5.4 NEG POS NEG No No No No No No cellulitis leg
12 28 30 1.9 162 18 0.7 1 80 56 187 24 5.8 3.6 2.2 130 4.9 NEG NEG NEG
56 36 20 1.8 132 42 0.8 44 42 186 62 390 46 5.7 2.5 3.2 128 5.4 NEG NEG NEG Yes No Yes No Yes No
12 30 20 1.4 144 18.8 0.6 11.4 8.7 155 55 199 24 5.1 2 3.1 122.4 4.6 NEG NEG NEG Yes No No No No Yes
18 36 26 2 168 60.3 0.77 12.6 10.4 11 12 420 74 4.3 2 2.3 110 4.2 NEG NEG NEG Yes No Yes No No Yes
80 28 16 1.3 85 63.75 1.16 7 5.8 78 38 182 17 5.3 2 3.3 138.2 4.3 NEG NEG NEG Yes No No No Yes Yes
14 28 17 1.2 133 37.18 0.72 10.1 7.6 137 69 366 243 4.4 2 2.4 128 3.6 NEG NEG NEG Yes No No No No Yes old PT
15 34 19 1.4 97 49.2 1.6 9.7 7.5 76 70 130 138 6.9 2.6 4.3 132 4.2 NEG NEG NEG No Yes No No No Yes
12 28 19 1.4 97 27 0.4 9.4 5.6 170 127 314 49 6 2.4 3.6 134 2.8 NEG NEG NEG Yes No No No No No
28 28 17 1.6 110 15.4 0.9 3.3 2 84 39 236 18 5.7 2.1 3.6 133 4 NEG POS NEG Yes No Yes No No No
80 28 16 1.4 122 32.5 1.8 1 0.5 43 20 130 14 4.7 2.3 2.4 136 4.8 NEG NEG NEG Yes Yes No No No No Obesity
12 28 15 1.2 84 22.9 1.34 5.2 3.6 48 42 156 14 5.5 2.2 3.3 142 4.5 NEG NEG NEG No No No No No Yes
12 28 17 1.2 286 10.33 0.63 1.25 0.66 69 37 209 80 6.7 2 4.7 129 4.5 NEG POS NEG No No No No No Yes DM
36 30 23 1.8 88 54.4 1.04 3.4 2.1 81 26 97 24 5.3 2 3.3 136 3.2 NEG NEG NEG Yes No Yes No No No
18 30 23 1.7 65 56.6 1.09 26.9 24.6 166 68 405 73 6.5 2.8 3.7 116 3.2 NEG NEG NEG Yes No Yes No No Yes
16 32 20 1.4 121 48 1.2 1 0.8 52 32 456 22 5.6 2 3.6 110 4.6 NEG NEG NEG Yes No No No No No
84 42 35 2.6 109 36.3 1.2 7.7 5.2 52 24 197 21 5.7 2 3.7 132 4.5 NEG NEG NEG No No Yes No No No cellulitis leg
8 28 16 1.2 100 37.11 1.41 1.24 0.69 79 22 238 278 5.6 2 3.6 135 3.6 NEG NEG NEG No No No No No Yes
16 26 16 1.1 74 18.7 0.48 1.2 1 85 92 254 23 4.7 2.2 2.5 140 4.4 NEG POS NEG No No No No No Yes
16 30 21 1.5 101 29 1 8.1 6.7 73 59 287 39 7.2 3.3 3.9 110 2.8 NEG NEG NEG Yes No Yes No No No
56 32 19 1.3 211 66.49 3.2 3.2 2 24 12 433 133 6.7 2.7 4 120 2.8 NEG NEG NEG No Yes No No No No DM
14 28 16 1.2 88 53.8 1.31 1.2 0.6 91 34 194 170 7.2 2.6 4.6 124 5.2 NEG NEG NEG Yes No No No No Yes
128 30 17 1.4 195 25.53 1.06 0.59 0.3 38 27 171 49 5.9 1.7 4.2 118 4.6 NEG NEG NEG Yes No No No No No DM
28 32 18 1.3 93 50.4 1.39 1.5 0.9 87 67 281 84 5.2 2 3.2 131 5.4 NEG NEG NEG Yes No No No No No
110 34 23 1.7 228 70.8 2.1 5.42 3.8 43 36 184 58 5.4 1.7 3.7 125 5.2 NEG NEG NEG No Yes Yes No No Yes DM
80 38 28 2.1 199 51.74 2.19 4.2 2.5 26 12 220 26 4.8 2 2.8 128 2.74 NEG NEG NEG Yes Yes Yes No No Yes DM
74 26 26 1.9 282 57.07 0.63 3.7 1.5 46 18 153 23 4 1.1 2.9 119 4.6 NEG NEG NEG No No Yes No Yes Yes DM
42 34 27 1.9 88 13.22 0.9 4.12 3.64 72 46 267 17 7.1 2.4 4.7 116 3.4 NEG NEG NEG Yes No Yes No No No
54 33 22 1.7 217 47 0.8 7.7 5.6 51 34 273 29 5.6 2.3 3.3 136 3.4 NEG NEG POS Yes No Yes No No No DM
22 26 14 1 278 74 1.15 2.1 1.4 41 28 289 18 8.1 2.3 5.8 124 5.2 NEG NEG NEG Yes No No No No Yes DM
15 28 15 1.1 155 18.5 0.54 1.7 1.3 37 31 286 18 6.3 2.6 3.7 142 3.6 NEG NEG NEG No No No No No Yes DM
12 36 24 1.8 109 23.72 0.81 4.4 2.1 206 79 714 69 6.3 2.5 3.8 140 3.5 NEG NEG NEG Yes No Yes No Yes No
24 28 14 1 129 17 0.8 2.1 1 31 11 169 4 5.1 2.6 2.5 126 4.2 NEG NEG NEG Yes No No No No Yes
36 32 19 1.4 84 16 1 3 0.5 122 59 184 43 5.4 2.5 2.9 127 4.6 NEG NEG NEG Yes No No Yes No No
12 34 24 1.7 82 22.09 0.47 4.5 2 76 66 589 469 6.9 3.2 3.7 126.2 4.4 NEG POS NEG
20 26 18 1.4 85 29.4 0.9 7.1 5.8 93 25 278 253 5.3 2 3.3 118 4.6 NEG NEG NEG Yes No No No No Yes
15 26 18 1.3 44 24.8 1.5 12.12 10.76 62 26 395 45 6.5 2.5 4 119 2.8 NEG NEG NEG Yes No No No No No
40 36 26 1.9 78 84 3.5 9.4 6.22 90 50 172 90 7 2 5 134 4.5 NEG NEG NEG No Yes Yes No No No
62 38 30 2.2 144 39.6 0.4 7.6 3.1 50 10 287 32 7.6 2.4 5.2 123 2.1 NEG NEG NEG No No Yes No Yes No
32 32 20 1.4 104 32.37 0.82 1.8 1 600 330 129 84 5.9 2.2 3.7 137.6 3.62 NEG NEG NEG Yes No No No No No
30 38 26 1.3 77 35 1 15.1 11 23 50 628 175 6 2.6 3.4 142 4.6 NEG NEG NEG Yes No No No No No
40 32 30 2.1 115 13.8 0.62 5.8 3.3 65 22 227 25 8.4 2.4 6 138.3 3.79 NEG NEG NEG Yes No Yes No No No
100 28 16 1.2 228 112.28 1.8 1.9 1.5 180 47 700 183 7.5 2.3 5.2 136 4.2 NEG NEG NEG No Yes No No No Yes DM
40 26 14 1 84 25.23 0.54 4 2 27 11 157 15 6.1 3.8 2.3 137.7 3.3 NEG NEG NEG Yes No No No No Yes
24 30 19 1.4 60 23.3 0.7 14.1 9.2 114 52 354 30 7.5 2.8 4.7 118 4.8 NEG NEG NEG Yes No No No Yes No
28 32 21 1.6 68 13.97 0.8 2.2 1.3 37 17 395 40 4.7 1.7 4 133.3 4.33 NEG POS NEG Yes No Yes No No No
31 24 19 1.4 113 41.5 1.83 6.9 4 42 26 169 14 7.1 2.9 4.2 123 5 NEG NEG NEG Yes Yes No No No Yes
72 30 19 1.2 95 80 3.5 5.1 3.9 42 39 482 34 7.1 2.5 5.6 118 3.2 NEG NEG NEG No Yes No No No No
42 34 26 1.8 64 76 1.1 10.9 7.8 167 81 285 32 3.7 2.1 1.6 132 5.2 NEG NEG NEG Yes No Yes No No No
52 34 22 1.6 170 40.69 1.2 2.2 1 21 17 86 6 6.2 2.6 3.6 132 4.24 NEG NEG POS
96 40 39 2.9 113 13.91 0.8 10.7 6.8 36 14 260 154 5.1 2 3.1 134.3 4.5 NEG NEG NEG Yes No Yes No No No DM
42 32 22 1.6 150 24.2 0.8 3.8 2.4 85 69 153 42 7.7 2 3.7 120 3.6 NEG NEG NEG No No Yes No Yes No
32 34 19 1.4 73 12.74 0.84 3.4 1.76 101 43 197 41 5.6 2 3.6 115 4.2 NEG NEG NEG No No No No No Yes
42 28 16 1.1 99 23.35 0.67 0.76 0.52 74 54 161 21 6.5 3.1 3.4 141.7 4.92 NEG NEG POS No No No No No Yes old PT
15 42 20.6 1.6 78 22 1.1 4.9 3.4 27 18 252 54 5.6 2.8 2.8 130.5 5.32 NEG NEG NEG Yes No Yes No No Yes
48 34 22 1.6 144 16.11 0.65 5.2 3 65 21 340 205 5.4 2 3.4 139 4.37 NEG NEG NEG Yes No Yes No No Yes Seizure
gg
